Document:

Exhibit 10.4

 

AMENDMENT TO
EMPLOYMENT AGREEMENT

 

THIS AMENDMENT TO EMPLOYMENT AGREEMENT, made as of
the 15th day of July 2022, by and between PENNS WOODS BANCORP, INC. (“Penns Woods”), a Pennsylvania business corporation,
and BRIAN L. KNEPP, and adult individual (“Executive”).

 

BACKGROUND

 

1. Penns Woods and Executive are presently parties
to an amended and restated employment agreement, dated as of December 31, 2018 (the “Employment Agreement”).

 

2. Penns Woods and Executive desire to amend the
Employment Agreement in certain respects as set forth herein.

 

AGREEMENT:

 

NOW, THEREFORE, the parties hereto, intending to
be legally bound, agree as follows:

 

1. Amendment to Section 2 of Employment Agreement.
Section 2 of the Employment Agreement is hereby amended and restated in its entirety to read as follows:

 

“Titles and Duties of Executive.
Executive shall perform and discharge well and faithfully such management and administrative duties as an executive officer of Penns Woods
as may be assigned to him from time to time by the Board of Directors of Penns Woods, as applicable, and which are consistent with his
positions set forth in the following sentence. Executive shall be employed as President and Chief Financial Officer of Penns Woods. Executive
shall report directly to the Chief Executive Officer of Penns Woods. Executive shall devote his full time, attention and energies to the
business of Penns Woods and its affiliated companies during the Employment Period (as defined in Section 3); provided, however, that this
section shall not be construed as preventing Executive from (a) investing his personal assets in enterprises that do not compete with
Penns Woods or any of its majority-owned subsidiaries (except as an investor owning less than 5% of the stock of a publicly-owned company),
or (b) being involved in any civic, community or other activities with the prior approval of the Board of Directors of Penns Woods.”

 

2. Amendment to Section 3(a) of Employment
Agreement. Section 3(a) of the Employment Agreement is hereby amended and restated in its entirety as follows:

 

“(a) This Agreement shall
be for a period (the “Employment Period”) commencing on the date of this Agreement and ending on July 14, 2024;
provided, however, that, commencing on July 15, 2024 and on July 15 of each succeeding year (each an “Annual Renewal
Date”), the Employment Period shall be automatically extended for one (1) additional year from the applicable Annual Renewal
Date, unless Penns Woods or Executive shall give written notice of nonrenewal to the other party at least sixty (60) days prior to
an Annual Renewal Date, in which event this Agreement shall terminate at the end of the then existing Employment Period. Neither the
expiration of the Employment Period, nor the termination of this Agreement, shall affect the enforceability of the provisions of
Sections 7, 8 and 9.”

 

    1 

     

    

 

3. Amendments to Sections 3(b)(ii) and 3(b)(iii)
of Employment Agreement. The references to “CFG” in Sections 3(b)(ii) and 3(b)(iii) are hereby deleted.

 

4. Amendment to Section 4(a) of Employment
Agreement. Section 4(a) of the Employment Agreement is hereby amended and restated in its entirety as follows:

 

“(a) Salary. During the
Employment Period, Executive shall be paid a base salary at the rate of $257,500 per year, payable bi-weekly at such times as salaries
are paid to other executive officers of Penns Woods. The Board of Directors of Penns Woods, or applicable Board Committee, shall review
Executive’s base salary annually and may, from time to time, in its discretion increase Executive’s base salary. Any and all
such increases in base salary shall be deemed to constitute amendments to this subsection to reflect the increased amounts, effective
as of the dates established for such increases by appropriate corporate action.”

 

5. Amendment of Section 4(f) of the Employment
Agreement. Section 4(f) of the Employment Agreement is hereby amended and restated in its entirety to read as follows:

 

“(f)  Cellular Phone
and Phone Number. In the event that Executive’s employment with Penns Woods terminates for any reason, Executive shall be permitted
to retain the cellular telephone provided by the Company to Executive, including the cellular phone number. Expenses related to use of
any cellular telephone retained by Executive following a termination of employment shall be paid by Executive.”

 

6. Amendment of Section 5(a) of the Employment
Agreement. Section 5(a) of the Employment Agreement is hereby amended and restated in its entirety to read as follows:

 

“(a) Benefits. If a
Change in Control (as defined below) shall occur and concurrently therewith or during a period of twenty-four (24) months thereafter
Executive’s employment hereunder is terminated by Penns Woods without Cause (other than for the reasons set forth in Section
3(d)) or by Executive with Good Reason (as defined below), Executive shall be entitled to receive a lump-sum cash payment, no later
than thirty (30) days following the date of such termination, in an amount equal to two (2.0) times the sum of (i) Executive’s
annual base salary then in effect (or immediately prior to any reduction resulting in a termination for Good Reason) and (ii) the
average of the last three (3) annual bonuses paid to Executive. In addition, during the twenty four (24) month period following
Executive’s termination of employment that is subject to this Section 6(a), Executive shall be permitted to continue
participation in, and Penns Woods shall maintain the same level of contribution for, Executive’s participation in the
medical/health insurance plan or program in effect with respect to Executive during the one (1) year period prior to his termination
of employment, or, if Penns Woods is not permitted to provide such benefits because Executive is no longer an employee or as a
result of any applicable legal requirement, Executive shall receive a dollar amount, on or within thirty (30) days following the
date of termination, equal to the cost to Executive of obtaining such benefits (or substantially similar benefits).”

 

    2 

     

    

 

7. Ratification of Agreement. Except as
otherwise provided in this Amendment to Employee Agreement, all terms and conditions of the Employment Agreement remain in full force
and effect, and nothing contained in this Amendment to Employment Agreement shall be deemed to alter or amend any provision of the Employment
Agreement except as specifically provided herein. References in the Employment Agreement to the “Agreement” shall be deemed
to be references to the Agreement as amended hereby.

 

8. Waiver. No provision of this Amendment
to Employment Agreement may be modified, waived, or discharged unless such waiver, modification, or discharge is agreed to in writing
and signed by Executive and Penns Woods. No waiver by any party hereto at any time of any breach by the other party hereto of, or compliance
with, any condition or provision of this Amendment to Employment Agreement to be performed by such other party shall be deemed a waiver
of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.

 

9. Assignment. This Amendment to Employment
Agreement shall not be assignable by any party, except by Penns Woods to any affiliated company or to any successor in interest to its
businesses.

 

10. Entire Agreement. This Amendment to
Employment Agreement contains the entire agreement of the parties relating to the subject matter hereof.

 

11. Applicable Law. This Agreement shall
be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without regard to its conflict of laws principles.

 

    3 

     

    

 

IN WITNESS
WHEREOF, the parties have executed this Amendment to Employment Agreement as of the date first above written.

 

	 	PENNS WOODS BANCORP, INC.

 

		By:	/s/ Christine
                                            M. Barto

	 	Name: Christine M. Barto
	 	Title: Senior Vice President/Chief Human  Resource Officer

 

	 	(“Penns Woods”)

 

	 	/s/ Brian L. Knepp

	 	Brian L. Knepp

 

	 	(“Executive”)

 

    4Exhibit 10.1

 

Certain portions
of this document have been omitted pursuant to Item 601(a)(6) of Regulation S-K and, where applicable, have been marked with
 “[***]” to indicate where omissions have been made.

 

PURCHASE AGREEMENT

 

THIS
PURCHASE AGREEMENT (the "Agreement"), dated as of July 21, 2022, is made by and between ZYNERBA PHARMACEUTICALS, INC.,
a Delaware corporation (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability
company (the "Investor").

 

WHEREAS:

 

Subject to the terms and conditions
set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to Twenty
Million Dollars ($20,000,000) of the Company’s common stock, $0.001 par value per share (the "Common Stock"). The
shares of Common Stock to be purchased hereunder are referred to herein as the "Purchase Shares."

 

NOW THEREFORE, in consideration
of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Company and the Investor hereby agree as follows:

 

		1.	CERTAIN DEFINITIONS.

 

For purposes of this Agreement,
the following terms shall have the following meanings:

 

(a)            "Accelerated
Purchase Date" means, with respect to any Accelerated Purchase made pursuant to Section 2(b) hereof, the Business
Day immediately following the applicable Purchase Date with respect to the corresponding Regular Purchase referred to in Section 2(b) hereof.

 

(b)            "Accelerated
Purchase Minimum Price Threshold" means, with respect to any Accelerated Purchase made pursuant to Section 2(b) hereof,
any minimum per share price threshold set forth by the Company in the applicable Accelerated Purchase Notice.

 

(c)            "Accelerated
Purchase Notice" means, with respect to any Accelerated Purchase made pursuant to Section 2(b) hereof, an irrevocable
written notice from the Company to the Investor directing the Investor to purchase the applicable Accelerated Purchase Share Amount at
the Accelerated Purchase Price on the Accelerated Purchase Date for such Accelerated Purchase in accordance with this Agreement, and specifying
any Accelerated Purchase Minimum Price Threshold determined by the Company.

 

(d)            "Accelerated
Purchase Price" means, with respect to any Accelerated Purchase made pursuant to Section 2(b) hereof, the lower
of ninety-seven percent (97%) of (i) the VWAP for the period beginning at 9:30:01 a.m., Eastern time, on the applicable Accelerated
Purchase Date, or such other time publicly announced by the Principal Market as the official open (or commencement) of trading on the
Principal Market on such applicable Accelerated Purchase Date (the "Accelerated Purchase Commencement Time"), and ending
at the earliest of (A) 4:00:00 p.m., Eastern time, on such applicable Accelerated Purchase Date, or such other time publicly announced
by the Principal Market as the official close of trading on the Principal Market on such applicable Accelerated Purchase Date, (B) such
time, from and after the Accelerated Purchase Commencement Time for such Accelerated Purchase, that the total number (or volume) of shares
of Common Stock traded on the Principal Market has exceeded the applicable Accelerated Purchase Share Volume Maximum, and (C) such
time, from and after the Accelerated Purchase Commencement Time for such Accelerated Purchase, that the Sale Price has fallen below the
applicable Accelerated Purchase Minimum Price Threshold (such earliest of (i)(A), (i)(B) and (i)(C) above, the "Accelerated
Purchase Termination Time"), and (ii) the Closing Sale Price of the Common Stock on such applicable Accelerated Purchase
Date (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other
similar transaction).

 

    

    

    

 

(e)            "Accelerated
Purchase Share Amount" means, with respect to any Accelerated Purchase made pursuant to Section 2(b) hereof,
the number of Purchase Shares directed by the Company to be purchased by the Investor in an Accelerated Purchase Notice, which number
of Purchase Shares shall not exceed the lesser of (i) 300% of the number of Purchase Shares directed by the Company to be purchased
by the Investor pursuant to the corresponding Regular Purchase Notice for the corresponding Regular Purchase referred to in Section 2(b) hereof
(subject to the Purchase Share limitations contained in Section 2(a) hereof) and (ii) an amount equal to (A) the
Accelerated Purchase Share Percentage multiplied by (B) the total number (or volume) of shares of Common Stock traded on the Principal
Market during the period on the applicable Accelerated Purchase Date beginning at the Accelerated Purchase Commencement Time for such
Accelerated Purchase and ending at the Accelerated Purchase Termination Time for such Accelerated Purchase.

 

(f)             "Accelerated
Purchase Share Percentage" means, with respect to any Accelerated Purchase made pursuant to Section 2(b) hereof,
thirty percent (30%).

 

(g)            "Accelerated
Purchase Share Volume Maximum" means, with respect to any Accelerated Purchase made pursuant to Section 2(b) hereof,
a number of shares of Common Stock equal to (i) the applicable Accelerated Purchase Share Amount properly directed by the Company
to be purchased by the Investor in the applicable Accelerated Purchase Notice for such Accelerated Purchase, divided by (ii) the
Accelerated Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock
split, reverse stock split or other similar transaction).

 

(h)            "Additional
Accelerated Purchase Date" means, with respect to any Additional Accelerated Purchase made pursuant to Section 2(c) hereof,
the Business Day (i) that is the Accelerated Purchase Date with respect to the corresponding Accelerated Purchase referred to in
Section 2(b) hereof and (ii) on which the Investor receives, prior to 1:00 p.m., Eastern time, on such Business
Day, a valid Additional Accelerated Purchase Notice for such Additional Accelerated Purchase in accordance with this Agreement.

 

(i)              "Additional
Accelerated Purchase Minimum Price Threshold" means, with respect to any Additional Accelerated Purchase made pursuant to Section 2(c) hereof,
any minimum per share price threshold set forth by the Company in the applicable Additional Accelerated Purchase Notice.

 

(j)             "Additional
Accelerated Purchase Notice" means, with respect to any Additional Accelerated Purchase made pursuant to Section 2(c) hereof,
an irrevocable written notice from the Company to the Investor directing the Investor to purchase the applicable Additional Accelerated
Purchase Share Amount at the Additional Accelerated Purchase Price for such Additional Accelerated Purchase in accordance with this Agreement,
and specifying any Additional Accelerated Purchase Minimum Price Threshold determined by the Company.

 

    -2-

    

    

 

(k)             "Additional
Accelerated Purchase Price" means, with respect to any Additional Accelerated Purchase made pursuant to Section 2(c) hereof,
the lower of ninety-seven percent (97%) of (i) the VWAP for the period on the applicable Additional Accelerated Purchase Date, beginning
at the latest of (A) the applicable Accelerated Purchase Termination Time with respect to the corresponding Accelerated Purchase
referred to in Section 2(c) hereof on such Additional Accelerated Purchase Date, (B) the applicable Additional Accelerated
Purchase Termination Time with respect to the most recently completed prior Additional Accelerated Purchase on such Additional Accelerated
Purchase Date, as applicable, and (C) the time at which all Purchase Shares subject to all prior Accelerated Purchases and Additional
Accelerated Purchases (as applicable), including, without limitation, those that have been effected on the same Business Day as the applicable
Additional Accelerated Purchase Date with respect to which the applicable Additional Accelerated Purchase relates, have theretofore been
received by the Investor as DWAC Shares in accordance with this Agreement (such latest of (i)(A), (i)(B) and (i)(C) above, the
 "Additional Accelerated Purchase Commencement Time"), and ending at the earliest of (X) 4:00 p.m., Eastern time,
on such Additional Accelerated Purchase Date, or such other time publicly announced by the Principal Market as the official close of trading
on the Principal Market on such Additional Accelerated Purchase Date, (Y) such time, from and after the Additional Accelerated Purchase
Commencement Time for such Additional Accelerated Purchase, that the total number (or volume) of shares of Common Stock traded on the
Principal Market has exceeded the applicable Additional Accelerated Purchase Share Volume Maximum, and (Z) such time, from and after
the Additional Accelerated Purchase Commencement Time for such Additional Accelerated Purchase, that the Sale Price has fallen below the
applicable Additional Accelerated Purchase Minimum Price Threshold (such earliest of (i)(X), (i)(Y) and (i)(Z) above, the "Additional
Accelerated Purchase Termination Time"), and (ii) the Closing Sale Price of the Common Stock on such Additional Accelerated
Purchase Date (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split
or other similar transaction).

 

(l)              "Additional
Accelerated Purchase Share Amount" means, with respect to any Additional Accelerated Purchase made pursuant to Section 2(c) hereof,
the number of Purchase Shares directed by the Company to be purchased by the Investor on an Additional Accelerated Purchase Notice, which
number of Purchase Shares shall not exceed the lesser of (i) 300% of the number of Purchase Shares directed by the Company to be
purchased by the Investor pursuant to the corresponding Regular Purchase Notice for the corresponding Regular Purchase referred to in
Section 2(c) hereof (subject to the Purchase Share limitations contained in Section 2(a) hereof) and
(ii) an amount equal to (A) the Additional Accelerated Purchase Share Percentage multiplied by (B) the total number (or
volume) of shares of Common Stock traded on the Principal Market during the period on the applicable Additional Accelerated Purchase Date
beginning at the Additional Accelerated Purchase Commencement Time for such Additional Accelerated Purchase and ending at the Additional
Accelerated Purchase Termination Time for such Additional Accelerated Purchase.

 

(m)            "Additional
Accelerated Purchase Share Percentage" means, with respect to any Additional Accelerated Purchase made pursuant to Section 2(c) hereof,
thirty percent (30%).

 

(n)            "Additional
Accelerated Purchase Share Volume Maximum" means, with respect to any Additional Accelerated Purchase made pursuant to Section 2(c) hereof,
a number of shares of Common Stock equal to (i) the applicable Additional Accelerated Purchase Share Amount properly directed by
the Company to be purchased by the Investor in the applicable Additional Accelerated Purchase Notice for such Additional Accelerated Purchase,
divided by (ii) the Additional Accelerated Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization,
non-cash dividend, stock split, reverse stock split or other similar transaction).

 

(o)            "Alternate
Adjusted Regular Purchase Share Limit" means, with respect to a Regular Purchase made pursuant to Section 2(a) hereof,
the maximum number of Purchase Shares which, taking into account the applicable per share Purchase Price therefor calculated in accordance
with this Agreement, would enable the Company to deliver to the Investor, on the applicable Purchase Date for such Regular Purchase, a
Regular Purchase Notice for a Purchase Amount equal to, or as closely approximating without exceeding, One Hundred Fifty Thousand ($150,000).

 

(p)            "Applicable
Law(s)" means, with respect to any Person, the common law and any federal, provincial, state, territorial, local, foreign, multinational
or international laws, statutes, codes, treaties, standards, rules and regulations, guidelines, ordinances, orders, judgments, writs,
injunctions, decrees or settlement agreements (including administrative or judicial precedents or authorities) and the interpretation
or administration thereof by, and other determinations, directives, requirements or requests of, any governmental authority, in each case
whether or not having the force of law and, in each case, that are applicable to or binding upon such Person or any of its property or
to which such Person or any of its property is subject.

 

    -3-

    

    

 

(q)            "Available
Amount" means, initially, Twenty Million Dollars ($20,000,000) in the aggregate, which amount shall be reduced by the Purchase
Amount each time the Investor purchases shares of Common Stock pursuant to Section 2 hereof.

 

(r)             "Bankruptcy
Law" means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.

 

(s)            "Base
Prospectus" means the Company’s final base prospectus, dated June 10, 2022, including the documents incorporated by
reference therein.

 

(t)             "Business
Day" means any day on which the Principal Market is open for trading, including any day on which the Principal Market is open
for trading for a period of time less than the customary time.

 

(u)            "Bylaws"
means the Company’s Amended and Restated Bylaws.

 

(v)            "Charter"
means the Company’s Sixth Amended and Restated Certificate of Incorporation.

 

(w)            "Closing
Sale Price" means, for any security as of any date, the last closing sale price for such security on the Principal Market as
reported by the Principal Market.

 

(x)             "Confidential
Information" means any information disclosed by either party to the other party, either directly or indirectly, in writing, orally
or by inspection of tangible objects (including, without limitation, documents, prototypes, samples, plant and equipment), which is designated,
either orally or in writing, as "Confidential," "Proprietary" or some similar designation. Information communicated
orally shall be considered Confidential Information if such information is confirmed in writing as being Confidential Information within
ten (10) Business Days after the initial disclosure. Confidential Information may also include information disclosed to a disclosing
party by third parties. Confidential Information shall not, however, include any information which (i) was publicly known and made
generally available in the public domain prior to the time of disclosure by the disclosing party; (ii) becomes publicly known and
made generally available after disclosure by the disclosing party to the receiving party through no action or inaction of the receiving
party; (iii) is already in the possession of the receiving party without confidential restriction at the time of disclosure by the
disclosing party as shown by the receiving party’s files and records; (iv) is obtained by the receiving party from a third
party and is not known by the receiving party to be a breach of such third party’s obligations of confidentiality; or (v) is
independently developed by the receiving party without use of or reference to the disclosing party’s Confidential Information, as
shown by documents and other competent evidence in the receiving party’s possession.

 

(y)            "Custodian"
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

 

(z)             "DTC"
means The Depository Trust Company, or any successor performing substantially the same function for the Company.

 

(aa)      "DWAC
Shares" means shares of Common Stock that are (i) issued in electronic form, (ii) freely tradable and transferable
and without restriction on resale and (iii) timely credited by the Company, once a DWAC notice is received, to the Investor’s
or its designee’s specified Deposit/Withdrawal at Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer
(FAST) Program, or any similar program hereafter adopted by DTC performing substantially the same function.

 

    -4-

    

    

 

(bb)      "Exchange
Act" means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

(cc)      "Fully
Adjusted Regular Purchase Share Limit" means, with respect to any reorganization, recapitalization, non-cash dividend, stock
split or other similar transaction from and after the date of this Agreement, the Regular Purchase Share Limit (as defined in Section 2(a) hereof)
in effect on the applicable date of determination, after giving effect to the full proportionate adjustment thereto made pursuant to Section 2(a) hereof
for or in respect of such reorganization, recapitalization, non-cash dividend, stock split or other similar transaction.

 

(dd)      "Initial
Prospectus Supplement" means the prospectus supplement of the Company relating to the Securities, including the accompanying
Base Prospectus, to be prepared and filed by the Company with the SEC pursuant to Rule 424(b)(5) under the Securities Act and
in accordance with Section 5(a) hereof, together with all documents and information incorporated therein by reference.

 

(ee)      "Material
Adverse Effect" means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results
of operations, operations, assets, business or financial condition of the Company and its Subsidiaries, taken as a whole, other than any
material adverse effect that resulted exclusively from (A) any change in the United States or foreign economies or securities or
financial markets in general that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (B) any
change that generally affects the industry in which the Company and its Subsidiaries operate that does not have a disproportionate effect
on the Company and its Subsidiaries, taken as a whole, (C) any change arising in connection with earthquakes, hostilities, acts of
war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage
or terrorism or military actions existing as of the date hereof that does not have a disproportionate effect on the Company and its Subsidiaries,
taken as a whole, (D) any action taken by the Investor, its affiliates or its or their successors and assigns with respect to the
transactions contemplated by this Agreement, (E) the effect of any change in Applicable Laws or accounting rules that does not
have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, or (F) any change resulting from compliance
with terms of this Agreement or the consummation of the transactions contemplated by this Agreement, or (iii) the Company’s
ability to perform in any material respect on a timely basis its obligations under any Transaction Document to be performed as of the
date of determination.

 

(ff)     "Maturity
Date" means the first day of the month immediately following the thirty-six (36) month anniversary of the Commencement Date.

 

(gg)     "PEA
Period" means the period commencing at 9:30 a.m., Eastern time, on the tenth (10th) Business Day immediately prior
to the filing of any post-effective amendment to the Registration Statement (as defined herein) or New Registration Statement (as such
term is defined in the Registration Rights Agreement), and ending at 9:30 a.m., Eastern time, on the Business Day immediately following,
the effective date of any post-effective amendment to the Registration Statement (as defined herein) or New Registration Statement (as
such term is defined in the Registration Rights Agreement).

 

(hh)     "Person"
means an individual or entity including but not limited to any limited liability company, a partnership, a joint venture, a corporation,
a trust, an unincorporated organization and a government or any department or agency thereof.

 

    -5-

    

    

 

(ii)            "Principal
Market" means The Nasdaq Global Market (or any nationally recognized successor thereto); provided, however, that in the event
the Company’s Common Stock is at any time not listed on The Nasdaq Global Market (or any nationally recognized successor thereto)
but is listed or traded on The Nasdaq Capital Market, The Nasdaq Global Select Market, the New York Stock Exchange, the NYSE American,
the NYSE Arca, the OTC Bulletin Board, or the OTCQX or OTCQB operated by the OTC Markets Group, Inc. (or any nationally recognized
successor to any of the foregoing), then the "Principal Market" shall mean such other market or exchange which then constitutes
the principal trading market for the Company’s Common Stock.

 

(jj)         "Prospectus"
means the Base Prospectus, as supplemented from time to time by any Prospectus Supplement (including the Initial Prospectus Supplement),
including the documents and information incorporated by reference therein.

 

(kk)       "Prospectus
Supplement" means any prospectus supplement to the Base Prospectus (including the Initial Prospectus Supplement) filed with the
SEC pursuant to Rule 424(b) under the Securities Act in connection with the transactions contemplated by this Agreement, including
the documents and information incorporated by reference therein.

 

(ll)         "Purchase
Amount" means, with respect to any Regular Purchase, any Accelerated Purchase, or any Additional Accelerated Purchase made hereunder,
as applicable, the portion of the Available Amount to be purchased by the Investor pursuant to Section 2 hereof.

 

(mm)     "Purchase
Date" means, with respect to a Regular Purchase made pursuant to Section 2(a) hereof, the Business Day on which
the Investor receives, after 4:00 p.m., Eastern time, but prior to 6:00 p.m., Eastern time, on such Business Day, a valid Regular Purchase
Notice for such Regular Purchase in accordance with this Agreement.

 

(nn)      "Purchase
Price" means, with respect to a Regular Purchase made pursuant to Section 2(a) hereof, the lower of: (i) the
lowest Sale Price on the Purchase Date for such Regular Purchase and (ii) the arithmetic average of the three (3) lowest Closing
Sale Prices for the Common Stock during the ten (10) consecutive Business Days ending on the Business Day immediately preceding
such Purchase Date for such Regular Purchase (in each case, to be appropriately adjusted for any reorganization, recapitalization, non-cash
dividend, stock split or other similar transaction that occurs on or after the date of this Agreement).

 

(oo)          "Registration
Rights Agreement" means that certain Registration Rights Agreement, of even date herewith between the Company and the Investor.

 

(pp)      "Registration
Statement" has the meaning set forth in the Registration Rights Agreement.

 

(qq)      "Regular
Purchase Notice" means, with respect to a Regular Purchase pursuant to Section 2(a) hereof, an irrevocable written
notice from the Company to the Investor directing the Investor to buy a specified number of Purchase Shares (subject to the Purchase Share
limitations contained in Section 2(a) hereof) at the applicable Purchase Price for such Regular Purchase in accordance
with this Agreement.

 

(rr)        "Sale
Price" means any trade price for the shares of Common Stock on the Principal Market as reported by the Principal Market.

 

    -6-

    

    

 

(ss)       "SEC"
means the U.S. Securities and Exchange Commission.

 

(tt)        "Securities"
means, collectively, the Purchase Shares and the Commitment Shares (as defined below).

 

(uu)      "Securities
Act" means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

(vv)      "Shelf
Registration Statement" means the Company’s existing registration statement on Form S-3 (File No. 333-264966),
initially filed on May 16, 2022, and declared effective by order of the SEC on June 10, 2022.

 

(ww)     "Subsidiary"
means any Person the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting stock
or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K promulgated under the
Securities Act.

 

(xx)           "Transaction
Documents" means, collectively, this Agreement and the schedules and exhibits hereto, the Registration Rights Agreement and the
schedules and exhibits thereto.

 

(yy)     "Transfer
Agent" means American Stock Transfer & Trust Company, LLC, or such other Person who is then serving as the transfer
agent for the Company in respect of the Common Stock.

 

(zz)     "VWAP"
means in respect of an Accelerated Purchase Date and an Additional Accelerated Purchase Date, as applicable, the volume weighted average
price of the Common Stock on the Principal Market, as reported on the Principal Market.

 

		2.	PURCHASE OF COMMON STOCK.

 

Subject to the terms and conditions
set forth in this Agreement, the Company has the right, but not the obligation to sell to the Investor, in the Company’s sole and
absolute discretion, and the Investor has the obligation to purchase from the Company, Purchase Shares as follows:

 

    -7-

    

    

 

(a)            Commencement
of Regular Sales of Common Stock. Beginning one (1) Business Day following the satisfaction of the conditions set forth in
Sections 7 and 8 hereof (the "Closing" and the date of satisfaction of such conditions the "Commencement
Date") and thereafter, the Company shall have the right, but not the obligation, to direct the Investor, by its delivery to
the Investor of a Regular Purchase Notice from time to time, to purchase up to One Hundred Fifty Thousand (150,000) Purchase Shares,
provided that the Closing Sale Price of the Common Stock on the applicable Purchase Date is not below $0.10 and subject to
adjustment as set forth below in this Section 2(a) (such maximum number of Purchase Shares, as may be adjusted from time
to time, the "Regular Purchase Share Limit"), at the Purchase Price on the Purchase Date (each such purchase a
 "Regular Purchase"); provided, however, that the Regular Purchase Share Limit shall be increased to:
(i) Two Hundred Thousand (200,000) Purchase Shares, if the Closing Sale Price of the Common Stock on the applicable Purchase
Date is not below $1.00, (ii) Two Hundred Fifty Thousand (250,000) Purchase Shares, if the Closing Sale Price of the Common
Stock on the applicable Purchase Date is not below $2.00 and (iii) Three Hundred Thousand (300,000) Purchase Shares if the
Closing Sale Price of the Common Stock on the applicable Purchase Date is not below $3.00 (all of which share and dollar amounts
shall be appropriately proportionately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other
similar transaction); provided, however, that if, after giving effect to the full proportionate adjustment to the
Regular Purchase Share Limit therefor, the Fully Adjusted Regular Purchase Share Limit then in effect would preclude the Company
from delivering to the Investor a Regular Purchase Notice hereunder for a Purchase Amount (calculated by multiplying (X) the
number of Purchase Shares equal to the Fully Adjusted Regular Purchase Share Limit, by (Y) the Purchase Price per Purchase
Share covered by such Regular Purchase Notice on the applicable Purchase Date therefor) equal to or greater than the Alternate
Adjusted Regular Purchase Share Limit, the Regular Purchase Share Limit for such Regular Purchase Notice shall not be fully adjusted
to equal the applicable Fully Adjusted Regular Purchase Share Limit, but rather the Regular Purchase Share Limit for such Regular
Purchase Notice shall be adjusted to equal the applicable Alternate Adjusted Regular Purchase Share Limit as of the applicable
Purchase Date for such Regular Purchase Notice; and provided, further, however, that the Investor’s
committed obligation under any single Regular Purchase, other than any Regular Purchase with respect to which an Alternate Adjusted
Regular Purchase Share Limit shall apply, shall not exceed Two Million Dollars ($2,000,000) and provided, further, however,
that the parties may mutually agree at any time to increase the dollar amount of any Regular Purchase on any Purchase Date to a
dollar amount greater than the limit then in effect. If the Company delivers any Regular Purchase Notice for a Purchase Amount in
excess of the limitations contained in the immediately preceding sentence, such Regular Purchase Notice shall be void ab
initio only with respect to the extent of the amount by which the number of Purchase Shares set forth in such Regular Purchase
Notice exceeds the number of Purchase Shares which the Company is permitted to include in such Purchase Notice in accordance
herewith, and the Investor shall have no obligation to purchase such excess Purchase Shares in respect of such Regular Purchase
Notice; provided, however, that the Investor shall remain obligated to purchase the number of Purchase Shares which
the Company is permitted to include in such Regular Purchase Notice. The Company may deliver a Regular Purchase Notice to the
Investor on any Business Day, provided the Company has not failed to deliver Purchase Shares for the most recent prior Regular
Purchase. Notwithstanding the foregoing, the Company shall not deliver any Regular Purchase Notices during the PEA Period.

 

(b)            Accelerated
Purchases. Subject to the terms and conditions of this Agreement, from and after one (1) Business Day following the Commencement
Date, in addition to purchases of Purchase Shares as described in Section 2(a) above, the Company shall also have the
right, but not the obligation, to direct the Investor, by its delivery to the Investor of an Accelerated Purchase Notice from time to
time in accordance with this Agreement, to purchase the applicable Accelerated Purchase Share Amount at the Accelerated Purchase Price
on the Accelerated Purchase Date therefor in accordance with this Agreement (each such purchase, an "Accelerated Purchase");
provided, however, that the parties may mutually agree to increase the Accelerated Purchase Share Amount for any Accelerated
Purchase. The Company may deliver an Accelerated Purchase Notice to the Investor only on a Purchase Date on which the Company also properly
submitted a Regular Purchase Notice providing for a Regular Purchase of a number of Purchase Shares not less than the Regular Purchase
Share Limit then in effect on such Purchase Date in accordance with this Agreement (including, without limitation, giving effect to any
automatic increase to the Regular Purchase Share Limit as a result of the Closing Sale Price of the Common Stock exceeding certain thresholds
set forth in Section 2(a) above on such Purchase Date and any other adjustments to the Regular Purchase Share Limit,
in each case pursuant to Section 2(a) above). If the Company delivers any Accelerated Purchase Notice directing the Investor
to purchase an amount of Purchase Shares that exceeds the Accelerated Purchase Share Amount that the Company is then permitted to include
in such Accelerated Purchase Notice, such Accelerated Purchase Notice shall be void ab initio only with respect to the extent of
the amount by which the number of Purchase Shares set forth in such Accelerated Purchase Notice exceeds the Accelerated Purchase Share
Amount that the Company is then permitted to include in such Accelerated Purchase Notice (which shall be confirmed in an Accelerated Purchase
Confirmation), and the Investor shall have no obligation to purchase such excess Purchase Shares in respect of such Accelerated Purchase
Notice; provided, however, that the Investor shall remain obligated to purchase the Accelerated Purchase Share Amount which
the Company is permitted to include in such Accelerated Purchase Notice. Within one (1) Business Day after completion of each Accelerated
Purchase Date for an Accelerated Purchase, the Investor will provide to the Company a written confirmation of such Accelerated Purchase
setting forth the applicable Accelerated Purchase Share Amount and Accelerated Purchase Price for such Accelerated Purchase (each, an
 "Accelerated Purchase Confirmation"). Notwithstanding the foregoing, the Company shall not deliver any Accelerated Purchase
Notices during the PEA Period.

 

    -8-

    

    

 

(c)            Additional
Accelerated Purchases. Subject to the terms and conditions of this Agreement, from and after one (1) Business Day following
the Commencement Date, in addition to purchases of Purchase Shares as described in Section 2(a) and Section 2(b) above,
the Company shall also have the right, but not the obligation, to direct the Investor, by its timely delivery to the Investor of an
Additional Accelerated Purchase Notice on an Additional Accelerated Purchase Date in accordance with this Agreement, to purchase the
applicable Additional Accelerated Purchase Share Amount at the applicable Additional Accelerated Purchase Price therefor in
accordance with this Agreement (each such purchase, an "Additional Accelerated Purchase"); provided, however,
that the parties may mutually agree to increase the Additional Accelerated Purchase Share Amount for any Additional Accelerated
Purchase. The Company may deliver multiple Additional Accelerated Purchase Notices to the Investor on an Additional Accelerated
Purchase Date; provided, however, that the Company may deliver an Additional Accelerated Purchase Notice to the
Investor only (i) on a Business Day that is also the Accelerated Purchase Date for an Accelerated Purchase with respect to
which the Company properly submitted to the Investor an Accelerated Purchase Notice in accordance with this Agreement on the
applicable Purchase Date for a Regular Purchase of a number of Purchase Shares not less than the Regular Purchase Share Limit then
in effect in accordance with this Agreement (including, without limitation, giving effect to any automatic increase to the Regular
Purchase Share Limit as a result of the Closing Sale Price of the Common Stock exceeding certain thresholds set forth in Section 2(a) above
on such Purchase Date and any other adjustments to the Regular Purchase Share Limit, in each case pursuant to Section 2(a) above),
and (ii) if all Purchase Shares subject to all prior Regular Purchases, Accelerated Purchases and Additional Accelerated
Purchases, including, without limitation, those that have been effected on the same Business Day as the applicable Additional
Accelerated Purchase Date with respect to which the applicable Additional Accelerated Purchase relates, in each case have
theretofore been received by the Investor as DWAC Shares in accordance with this Agreement. If the Company delivers any Additional
Accelerated Purchase Notice directing the Investor to purchase an amount of Purchase Shares that exceeds the Additional Accelerated
Purchase Share Amount that the Company is then permitted to include in such Additional Accelerated Purchase Notice, such Additional
Accelerated Purchase Notice shall be void ab initio only with respect to the extent of the amount by which the number of
Purchase Shares set forth in such Additional Accelerated Purchase Notice exceeds the Additional Accelerated Purchase Share Amount
that the Company is then permitted to include in such Additional Accelerated Purchase Notice (which shall be confirmed in an
Additional Accelerated Purchase Confirmation), and the Investor shall have no obligation to purchase such excess Purchase Shares in
respect of such Additional Accelerated Purchase Notice; provided, however, that the Investor shall remain obligated to
purchase the Additional Accelerated Purchase Share Amount which the Company is permitted to include in such Additional Accelerated
Purchase Notice. Within one (1) Business Day after completion of each Additional Accelerated Purchase Date, the Investor will
provide to the Company a written confirmation of each Additional Accelerated Purchase on such Additional Accelerated Purchase Date
setting forth the applicable Additional Accelerated Purchase Share Amount and Additional Accelerated Purchase Price for each such
Additional Accelerated Purchase on such Additional Accelerated Purchase Date (each, an "Additional Accelerated Purchase
Confirmation"). Notwithstanding the foregoing, the Company shall not deliver any Additional Accelerated Purchase Notices
during the PEA Period.

 

    -9-

    

    

 

(d)            Compliance
with Principal Market Rules. Notwithstanding anything in this Agreement to the contrary, and in addition to the limitations set
forth in Section 2(e), the Company shall not issue more than 8,898,867 shares (including the Commitment Shares) of
Common Stock (the "Exchange Cap") under this Agreement, which equals 19.99% of the Company’s outstanding
shares of Common Stock as of the date hereof, unless stockholder approval is obtained to issue in excess of the Exchange Cap; provided, however,
that the foregoing limitation shall not apply if at any time the Exchange Cap is reached and at all times thereafter the average
price paid for all shares of Common Stock issued under this Agreement is equal to or greater than $1.13 (the "Minimum
Price"), a price equal to the lower of (i) the Nasdaq Official Closing Price immediately preceding the execution of
this Agreement and (ii) the arithmetic average of the five (5) Nasdaq Official Closing Prices for the Common Stock
immediately preceding the execution of this Agreement, as calculated in accordance with the rules of the Principal Market (in
such circumstance, for purposes of the Principal Market, the transaction contemplated hereby would not be "below market"
and the Exchange Cap would not apply). Notwithstanding the foregoing, the Company shall not be required or permitted to issue, and
the Investor shall not be required to purchase, any shares of Common Stock under this Agreement if such issuance would violate the
rules or regulations of the Principal Market. The Company may, in its sole discretion, determine whether to obtain stockholder
approval to issue more than 19.99% of its outstanding shares of Common Stock hereunder if such issuance would require stockholder
approval under the rules or regulations of the Principal Market. The Exchange Cap shall be reduced, on a share-for-share basis,
by the number of shares of Common Stock issued or issuable that may be aggregated with the transactions contemplated by this
Agreement under applicable rules of the Principal Market.

 

(e)            Payment
for Purchase Shares. For each Regular Purchase, the Investor shall pay to the Company an amount equal to the Purchase Amount with
respect to such Regular Purchase, as applicable, as full payment for such Purchase Shares via wire transfer of immediately available funds
on the same Business Day that the Investor receives such Purchase Shares, if such Purchase Shares are received by the Investor before
1:00 p.m., Eastern time, or, if such Purchase Shares are received by the Investor after 1:00 p.m., Eastern time, the next Business Day.
For each Accelerated Purchase and each Additional Accelerated Purchase, the Investor shall pay to the Company an amount equal to the Purchase
Amount with respect to such Accelerated Purchase and Additional Accelerated Purchase, respectively, as full payment for such Purchase
Shares via wire transfer of immediately available funds on the second (2nd) Business Day following the date that the Investor
receives such Purchase Shares. If the Company or the Transfer Agent shall fail for any reason or for no reason to electronically transfer
any Purchase Shares as DWAC Shares with respect to any Regular Purchase, Accelerated Purchase or Additional Accelerated Purchase (as applicable)
within two (2) Business Days following the receipt by the Company of the Purchase Price, Accelerated Purchase Price or Additional
Accelerated Purchase Price, respectively, therefor in compliance with this Section 2(e), and if on or after such Business
Day the Investor purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by
the Investor of such Purchase Shares that the Investor anticipated receiving from the Company in respect of such Regular Purchase, Accelerated
Purchase or Additional Accelerated Purchase (as applicable), then the Company shall, within two (2) Business Days after the Investor’s
request, either (i) pay cash to the Investor in an amount equal to the Investor’s total purchase price (including customary
brokerage commissions, if any) for the shares of Common Stock so purchased (the "Cover Price"), at which point the Company’s
obligation to deliver such Purchase Shares as DWAC Shares shall terminate, or (ii) promptly honor its obligation to deliver to the
Investor such Purchase Shares as DWAC Shares and pay cash to the Investor in an amount equal to the excess (if any) of the Cover Price
over the total Purchase Amount paid by the Investor pursuant to this Agreement for all of the Purchase Shares to be purchased by the Investor
in connection with such purchases. The Company shall not issue any fraction of a share of Common Stock upon any Regular Purchase, Accelerated
Purchase or Additional Accelerated Purchase. If the issuance would result in the issuance of a fraction of a share of Common Stock, the
Company shall round such fraction of a share of Common Stock up or down to the nearest whole share (with, for the avoidance of doubt,
a fractional share of 0.5 or higher being rounded up to the next whole share). All payments made under this Agreement shall be made in
lawful money of the United States of America or wire transfer of immediately available funds to such account as the Company may from time
to time designate by written notice in accordance with the provisions of this Agreement. Whenever any amount expressed to be due by the
terms of this Agreement is due on any day that is not a Business Day, the same shall instead be due on the next succeeding day that is
a Business Day.

 

    -10-

    

    

 

(f)            Beneficial
Ownership Limitation. Notwithstanding anything to the contrary contained in this Agreement, the Company shall not issue or sell, and
the Investor shall not purchase or acquire, any shares of Common Stock under this Agreement which, when aggregated with all other shares
of Common Stock then beneficially owned by the Investor and its affiliates (as calculated pursuant to Section 13(d) of the Exchange
Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by the Investor and its affiliates of more than
9.99% of the then issued and outstanding shares of Common Stock (the "Beneficial Ownership Limitation"). Upon the written
or oral request of the Investor, the Company shall promptly (but not later than one Business Day) confirm orally or in writing to the
Investor the number of shares of Common Stock then outstanding. The Investor and the Company shall each cooperate in good faith in the
determinations required hereby and the application hereof. The Investor shall promptly (but no later than one (1) Business Day after
obtaining such ownership) confirm to the Company when the total number of shares beneficially held by it and/or its affiliates exceeds
9.0% of the total outstanding amount of Common Stock then outstanding. The Investor’s written certification to the Company of the
applicability of the Beneficial Ownership Limitation, and the resulting effect thereof hereunder at any time, shall be conclusive with
respect to the applicability thereof and such result absent manifest error.

 

		3.	INVESTOR’S REPRESENTATIONS AND WARRANTIES.

 

The Investor represents and
warrants to the Company that as of the date hereof and as of the Commencement Date:

 

(a)            Organization,
Authority. Investor is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its
organization, with the requisite power and authority to enter into and to consummate the transactions contemplated by this Agreement
and the other Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder.

 

(b)            Investment
Purpose. The Investor is acquiring the Securities as principal for its own account for investment only and not with a view to or for
distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law,
has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities
law and has no direct or indirect arrangement or understandings with any other Persons to distribute or regarding the distribution of
such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting
the Investor’s right to sell the Securities at any time pursuant to the Registration Statement described herein or otherwise in
compliance with applicable federal and state securities laws). The Investor is acquiring the Securities hereunder in the ordinary course
of its business.

 

(c)            Accredited
Investor Status. The Investor is an "accredited investor" as that term is defined in Rule 501(a)(3) of Regulation
D promulgated under the Securities Act.

 

(d)            Information.
The Investor understands that its investment in the Securities involves a high degree of risk. The Investor (i) is able to bear the
economic risk of an investment in the Securities including a total loss thereof, (ii) has such knowledge and experience in financial
and business matters that it is capable of evaluating the merits and risks of the proposed investment in the Securities and (iii) has
had an opportunity to ask questions of and receive answers from the officers of the Company concerning the financial condition and business
of the Company and other matters related to an investment in the Securities. Neither such inquiries nor any other due diligence investigations
conducted by the Investor or its representatives shall modify, amend or affect the Investor’s right to rely on the Company’s
representations and warranties contained in Section 4 below. The Investor has sought such accounting, legal and tax advice
as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities and is not relying
on any accounting, legal tax or other advice from the Company or its officers, employees or representatives. The Investor acknowledges
and agrees that the Company neither makes nor has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 4 hereof.

 

    -11-

    

    

 

(e)            No
Governmental Review. The Investor understands that no U.S. federal or state agency or any other government or governmental agency
has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of an investment in the Securities
nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(f)            Validity;
Enforcement. This Agreement and the other Transaction Documents have been duly and validly authorized, executed and delivered on behalf
of the Investor and each is a valid and binding agreement of the Investor enforceable against the Investor in accordance with its terms,
subject as to enforceability to general principles of equity and to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation
and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(g)            Residency.
The Investor’s principal place of business is located in of the State of Illinois.

 

(h)            No
Short Selling. The Investor represents and warrants to the Company that at no time prior to the date of this Agreement has any of
the Investor, its agents (in their capacities as such), representatives or affiliates (in their capacities as such) engaged in or effected,
in any manner whatsoever, directly or indirectly, any (i) "short sale" (as such term is defined in Rule 200 of Regulation
SHO of the Exchange Act) of the Common Stock or (ii) hedging transaction that establishes a net short position with respect to the
Common Stock.

 

		4.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

The Company represents and
warrants to the Investor that, as of the date hereof and as of the Commencement Date:

 

(a)            Organization
and Qualification. The Company and each of its Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite corporate power and authority
to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any of its Subsidiaries
is in violation or default of any of the provisions of its respective certificate or articles of formation or incorporation, bylaws or
other organizational or charter documents, except as would not be expected to result in a Material Adverse Effect. Each of the Company
and its Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction
in which the nature of the business conducted or property owned by it makes such qualification necessary, and no proceeding has been instituted
in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification,
except where the failure to be so qualified or in good standing or such proceeding, as the case may be, would not reasonably be expected
to result in a Material Adverse Effect. The Company has no Subsidiaries except for the subsidiaries set forth on Exhibit 21.1 to
the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

 

    -12-

    

    

 

(b)            Authorization;
Enforcement; Validity. (i) The Company has the requisite corporate power and authority to enter into and perform its
obligations under this Agreement and each of the other Transaction Documents, and to issue the Securities in accordance with the
terms hereof and thereof, (ii) the execution and delivery of the Transaction Documents by the Company and the consummation by
it of the transactions contemplated hereby and thereby, including without limitation, the issuance of the Commitment Shares (as
defined below in Section 5(e)), the reservation for issuance and the issuance of the Purchase Shares issuable under this
Agreement, have been duly authorized by the Company’s board of directors, or a validly authorized committee thereof
(collectively, the "Board of Directors"), and no further consent or authorization is required by the Company, its
Board of Directors or any committee thereof, or its stockholders (save to the extent provided in this Agreement), (iii) this
Agreement has been, and each other Transaction Document shall be on the Commencement Date, duly executed and delivered by the
Company and (iv) this Agreement constitutes, and each other Transaction Document upon its execution on behalf of the Company,
shall constitute, the valid and binding obligations of the Company enforceable against the Company in accordance with their terms,
except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and
remedies. The Board of Directors of the Company has approved the resolutions (the "Signing Resolutions")
substantially in the form attached hereto as Exhibit A to authorize this Agreement and the transactions
contemplated hereby. The Signing Resolutions are valid, in full force and effect and have not been modified or supplemented in any
respect. The Company has delivered to the Investor a true and correct copy of a unanimous written consent adopting the Signing
Resolutions executed by all of the members of the Board of Directors of the Company. Except as set forth in this Agreement, no other
approvals or consents of the Board of Directors, any other authorized committee thereof, and/or stockholders is necessary under
Applicable Laws and the Company’s Charter and/or Bylaws to authorize the execution and delivery of this Agreement or any of
the transactions contemplated hereby, including, but not limited to, the issuance of the Commitment Shares and the issuance of the
Purchase Shares.

 

(c)            Capitalization.
As of the date hereof, the authorized capital stock of the Company consists of 200,000,000 shares of $0.001 par value Common Stock and
10,000,000 shares of $0.001 par value preferred stock. Except as disclosed in the SEC Documents (as defined below), (i) no shares
of the Company’s capital stock are subject to preemptive rights or any other similar rights or any liens or encumbrances suffered
or permitted by the Company, (ii) there are no outstanding debt securities, (iii) there are no outstanding options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into,
any shares of capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which
the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its
Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities
or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, (iv) there are no agreements or
arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of their securities under the
Securities Act (except the Registration Rights Agreement and those registration rights for which a registration statement has been filed
and is effective), (v) there are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain
any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or
any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries, (vi) there are no
securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities as described
in this Agreement and (vii) the Company does not have any stock appreciation rights or "phantom stock" plans or agreements
or any similar plan or agreement. The Company has furnished to the Investor true and correct copies of the Charter and the Bylaws, each
as in effect on the date hereof, and copies of any documents containing the material rights of holders of securities convertible or exercisable
for Common Stock, to the extent not filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2021 or any other Exchange Act reports.

 

    -13-

    

    

 

(d)            Issuance
of Securities. Upon issuance and payment therefor in accordance with the terms and conditions of this Agreement, the Purchase Shares
shall be validly issued, fully paid and nonassessable and free from all taxes, liens, charges, restrictions, rights of first refusal and
preemptive rights with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock.
10,000,000 shares of Common Stock have been duly authorized and reserved for issuance upon purchase under this Agreement as Purchase Shares.
347,222 shares of Common Stock (subject to equitable adjustment for any reorganization, recapitalization, non-cash dividend, stock split
or other similar transaction) have been duly authorized and reserved for issuance as Commitment Shares (as defined below in Section 5(e))
in accordance with this Agreement. Upon issuance in accordance with the terms and conditions of this Agreement, each of the Purchase Shares
and the Commitment Shares shall be validly issued, fully paid and nonassessable and free from all taxes, Liens, charges, restrictions,
rights of first refusal and preemptive rights with respect to the issue thereof, with the holders being entitled to all rights accorded
to a holder of Common Stock. The Securities are being issued pursuant to the Registration Statement. Upon receipt of the Purchase Shares
and the Commitment Shares, the Investor will have good and marketable title to such Securities and such Securities will be immediately
freely tradeable on the Principal Market by any holder who is not an "affiliate" of the Company under the Securities Act.

 

(e)             No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company
of the transactions contemplated hereby and thereby (including, without limitation, the reservation for issuance and issuance of the Purchase
Shares and the Commitment Shares) will not (i) result in a violation of the Charter, any certificate of designations, preferences
and rights of any outstanding series of preferred stock of the Company or the Bylaws or (ii) conflict with, or constitute a default
(or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or
result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations
and the rules and regulations of the Principal Market applicable to the Company or any of its Subsidiaries) or by which any property
or asset of the Company or any of its Subsidiaries is bound or affected, except in the case of conflicts, defaults, terminations, amendments,
accelerations, cancellations and violations under clause (ii), which would not reasonably be expected to result in a Material Adverse
Effect. Neither the Company nor any of its Subsidiaries is in violation of any term of or in default under its Charter, any certificate
of designation, preferences and rights of any outstanding series of preferred stock of the Company or Bylaws or their organizational charter
or bylaws, respectively. Neither the Company nor any of its Subsidiaries is in violation of any term of or is in default under any material
contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or regulation
applicable to the Company or its Subsidiaries, except for possible conflicts, defaults, terminations or amendments that would not reasonably
be expected to have a Material Adverse Effect. The business of the Company and its Subsidiaries is not being conducted, and shall not
be conducted, in violation of any law, ordinance or regulation of any governmental entity, except for possible violations, the sanctions
for which either individually or in the aggregate would not reasonably be expected to have a Material Adverse Effect. Except as specifically
contemplated by this Agreement and as required under the Securities Act or applicable state securities laws and the rules and regulations
of the Principal Market, the Company is not required to obtain any consent, authorization or order of, or make any filing or registration
with, any court or governmental agency or any regulatory or self-regulatory agency in order for it to execute, deliver or perform any
of its obligations under or contemplated by the Transaction Documents in accordance with the terms hereof or thereof. Except as set forth
elsewhere in this Agreement, (i) all consents, authorizations, orders, filings and registrations which the Company is required to
obtain pursuant to the preceding sentence on or prior to the date hereof or on or prior to the Commencement Date shall have been obtained
or effected on or prior to the date hereof and on or prior to the Commencement Date, respectively, and (ii) all consents, authorizations,
orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence with respect to the Commencement
shall be obtained or effected on or prior to the Commencement Date.

 

    -14-

    

    

 

(f)             SEC
Documents; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
for the twelve months preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such
material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with each
Prospectus, being collectively referred to herein as the "SEC Documents") on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Documents prior to the expiration of any such extension. As of their respective dates,
the SEC Documents complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable. None
of the SEC Documents, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be
stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading. The financial statements of the Company included in the SEC Documents comply in all material respects with applicable accounting
requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing. Such financial statements
have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the
periods involved ("GAAP"), except as may be otherwise specified in such financial statements or the notes thereto and
except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
and cash flows for the periods presented, subject, in the case of unaudited financial statements, to normal, immaterial, year-end audit
adjustments. Except as publicly available through the SEC’s Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system, the
Company has received no material notices or correspondence from the SEC for the one year preceding the date hereof other than SEC comment
letters relating to the Company’s filings under the Exchange Act and the Securities Act. There are no SEC comments that have not
been resolved to the satisfaction of the SEC staff. To the Company’s knowledge, the SEC has not commenced any enforcement proceedings
against the Company or any of its Subsidiaries.

 

(g)            Absence
of Certain Changes. Except as disclosed in the SEC Documents, since March 31, 2022, there has been no material adverse change
in the business, properties, operations, financial condition or results of operations of the Company or its Subsidiaries. For the avoidance
of doubt, neither a decrease in cash or cash equivalents or in the market price of the Common Stock nor losses incurred in the ordinary
course of the Company’s business shall be deemed or considered material adverse changes (it being understood and agreed that any
events, changes, effects, circumstances, facts, developments or occurrences giving rise to or contributing to such decreases or loss may
be taken into account in determining whether there has been, or would reasonably be expected to be, a material adverse change). The Company
has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy Law nor does the
Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy
or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as they become due.

 

(h)            Absence
of Litigation. Except as disclosed in the SEC Documents, there is no action, suit, proceeding, inquiry or investigation before or
by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any
of its Subsidiaries, threatened against the Company, the Common Stock or any of the Company’s or its Subsidiaries’ officers
or directors in their capacities as such, which would reasonably be expected to have a Material Adverse Effect.

 

(i)            Acknowledgment
Regarding Investor’s Status. The Company acknowledges and agrees that the Investor is acting solely in the capacity of arm’s
length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges
that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction
Documents and the transactions contemplated hereby and thereby and any advice given by the Investor or any of its representatives or agents
in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to the Investor’s
purchase of the Securities. The Company further represents to the Investor that the Company’s decision to enter into the Transaction
Documents has been based solely on the independent evaluation by the Company and its representatives and advisors.

 

    -15-

    

    

 

 

(j)            No
Aggregated Offering. Neither the Company, nor any of its affiliates, nor any Person acting on its or their behalf has, directly or
indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause
this offering of the Securities to be integrated or aggregated with prior offerings by the Company in a manner that would require stockholder
approval pursuant to the rules of the Principal Market on which any of the securities of the Company are listed or designated. The
issuance and sale of the Commitment Shares hereunder does not, and subject to the terms of this Agreement, the issuance and sale of the
additional Purchase Shares will not, contravene the rules and regulations of the Principal Market.

 

(k)            Intellectual
Property Rights. The Company and its Subsidiaries own or possess adequate rights or licenses to use all material trademarks, trade
names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals,
governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted, except as such
failure to own, possess or acquire such rights would not reasonably be expected, individually, or in the aggregate, to result in a Material
Adverse Effect. None of the Company’s material trademarks, trade names, service marks, service mark registrations, service names,
patents, patent rights, copyrights, inventions, licenses, approvals, government authorizations, trade secrets or other intellectual property
rights have expired or terminated, or, by the terms and conditions thereof, could expire or terminate within two years from the date
of this Agreement, except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Except
as set forth in the SEC Documents, the Company and its Subsidiaries do not have any knowledge of any infringement by the Company or its
Subsidiaries of any material trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service
marks, service mark registrations, trade secret or other similar rights of others, or of any such development of similar or identical
trade secrets or technical information by others, and there is no claim, action or proceeding that has been brought against, or to the
Company’s knowledge, being threatened against, the Company or its Subsidiaries regarding trademark, trade name, patents, patent
rights, invention, copyright, license, service names, service marks, service mark registrations, trade secret or other infringement,
which would reasonably be expected to have a Material Adverse Effect.

 

(l)            Environmental
Laws. The Company and its Subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws
and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants
or contaminants ("Environmental Laws"), (ii) have received all permits, licenses or other approvals required of
them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions
of any such permit, license or approval, except where, in each of the three foregoing clauses, the failure to so comply would not reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

(m)            Title.
Except as set forth in the SEC Documents, the Company and its Subsidiaries have good and marketable title in fee simple to all real property
owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and
its Subsidiaries, taken as a whole, in each case free and clear of all liens, encumbrances and defects ("Liens") and,
except for Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed
to be made of such property by the Company and its Subsidiaries and Liens for the payment of federal, state or other taxes, the payment
of which is neither delinquent nor subject to penalties, and Liens that would not reasonably be expected, individually or in the aggregate,
to result in a Material Adverse Effect. Any real property and facilities held under lease by the Company and its Subsidiaries are held
by them under valid, subsisting and enforceable leases with which the Company and its Subsidiaries are in compliance with such exceptions
as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and
its Subsidiaries, taken as a whole, except for such interference which would not reasonably be expected to have a Material Adverse Effect.

 

    -16-

    

    

 

(n)            Insurance.
The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks
and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its
Subsidiaries are engaged (including in respect of directors and officers liability insurance). Neither the Company nor any such Subsidiary
has been refused any insurance coverage sought or applied for and neither the Company nor any such Subsidiary has any reason to believe
that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from
similar insurers as may be necessary to continue its business at a cost that would not materially and adversely affect the condition,
financial or otherwise, or the earnings, business or operations of the Company and its Subsidiaries, taken as a whole.

 

(o)            Regulatory
Permits. Except as disclosed in the SEC Documents, the Company and its Subsidiaries possess all material certificates, authorizations
and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses
as currently conducted, except where the failure to possess such certificates, authorizations, or permits would not reasonably be expected
to have a Material Adverse Effect, and neither the Company nor any such Subsidiary has received any notice of proceedings relating to
the revocation or modification of any such material certificate, authorization or permit.

 

(p)            Compliance
with Laws. The Company is not in violation of any Applicable Law, except as would not reasonably be expected to have a Material Adverse
Effect.

 

(q)            Tax
Status. Except as disclosed in the SEC Documents, the Company and each of its Subsidiaries has made or filed all federal, state,
local or foreign income and all other material tax returns, reports and declarations required by any jurisdiction to which it is subject
(unless and only to the extent that the Company and each of its Subsidiaries has set aside on its books provisions reasonably adequate
for the payment of all unpaid and unreported taxes) and has paid all taxes and other governmental assessments and charges that are material
in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and has
set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such
returns, reports or declarations apply, and except as would not reasonably be expected to have a Material Adverse Effect. To the Company’s
knowledge, there are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction.

 

(r)            Transactions
With Affiliates. Except as disclosed in the SEC Documents, none of the Company’s stockholders, officers or directors or any
family member or affiliate of any of the foregoing, has either directly or indirectly an interest in, or is a party to, any transaction
that would be required to be disclosed as a related party transaction pursuant to Item 404 of Regulation S-K promulgated under the Securities
Act.

 

(s)            Application
of Takeover Protections. The Company and its board of directors have taken or will take prior to the Commencement Date all necessary
action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or other similar anti-takeover provision under the Charter or the laws of the state of its incorporation which
is or could become applicable to the Investor as a result of the transactions contemplated by this Agreement, including, without limitation,
the Company’s issuance of the Securities and the Investor’s ownership of the Securities.

 

    -17-

    

    

 

(t)            Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents or any other agreements
to be entered into by the Company and the Investor that, in each case, which shall be timely publicly disclosed by the Company, the Company
confirms that neither it nor any other Person acting on its behalf has provided the Investor or its agents or counsel with any information
that the Company believes constitutes or might reasonably constitute material, non-public information which is not otherwise disclosed
in the Registration Statement or the SEC Documents. The Company understands and confirms that the Investor will rely on the foregoing
representation in effecting purchases and sales of securities of the Company. All of the disclosure furnished by or on behalf of the
Company to the Investor regarding the Company, its business and the transactions contemplated hereby, including the disclosure schedules
to this Agreement, taken as a whole, is true and correct in all material respects and does not contain any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which
they were made, not misleading. The Company acknowledges and agrees that the Investor neither makes nor has made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3 hereof.

 

(u)            Foreign
Corrupt Practices. Neither the Company nor any of its Subsidiaries nor any director or officer, nor, to the knowledge of the
Company, any agent, employee or affiliate of the Company or any Subsidiary is aware of or has taken any action, directly or
indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the
rules and regulations thereunder (the "FCPA"), including, without limitation, making use of the mails or any
means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of
the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any
 "foreign official" (as such term is defined in the FCPA) or any foreign political party or official thereof or any
candidate for foreign political office, in contravention of the FCPA; and the Company, each of its Subsidiaries and, to the
knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and have instituted and
maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance
therewith. The operations of the Company and each of its Subsidiaries are and have been conducted at all times in compliance with
applicable financial recordkeeping and reporting requirements and the money laundering statutes and the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any applicable
governmental agency, including, without limitation, Title 18 U.S. Code section 1956 and 1957, the Patriot Act, the Bank Secrecy Act,
and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the
Financial Action Task Force on Money Laundering, of which the United States is a member and with which designation the United States
representative to the group or organization continues to concur, all as amended, and any Executive order, directive or regulation
pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder (collectively, the "Money
Laundering Laws"), and no action, suit or proceeding by or before any court or governmental agency, authority or body or
any arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the
knowledge of the Company, threatened. Neither the Company nor any of its Subsidiaries, nor to the knowledge of the Company any of
the directors, officers or employees, agents, affiliates or representatives of the Company or each of its Subsidiaries, is an
individual or entity that is, or is owned or controlled by an individual or entity that is: (i) the subject of any sanctions
administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control, the United Nations Security
Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively,
 "Sanctions"), nor (ii) located, organized or resident in a country or territory that is the subject of
Sanctions (including, without limitation, the Balkans, Belarus, Burma/Myanmar, Cote D’Ivoire, Cuba, Democratic Republic of
Congo, Iran, Iraq, Liberia, Libya, North Korea, Russia, Sudan, Syria, Venezuela and Zimbabwe). Neither the Company nor any
of its Subsidiaries will, directly or indirectly, use the proceeds of the transactions contemplated hereby, or lend, contribute or
otherwise make available such proceeds to any subsidiary, joint venture partner or other individual or entity: (i) to fund or
facilitate any activities or business of or with any individual or entity or in any country or territory that, at the time of such
funding or facilitation, is the subject of Sanctions or (ii) in any other manner that will result in a violation of Sanctions
by any individual or entity (including any individual or entity participating in the transactions contemplated hereby, whether as
underwriter, advisor, investor or otherwise). For the past five years, neither the Company nor any of its Subsidiaries has knowingly
engaged in, and is not now knowingly engaged in, any dealings or transactions with any individual or entity, or in any country or
territory, that at the time of the dealing or transaction is or was the subject of Sanctions.

 

    -18-

    

    

 

(v)            DTC
Eligibility. The Company, through the Transfer Agent, currently participates in the DTC Fast Automated Securities Transfer (FAST)
Program and the Common Stock can be transferred electronically to third parties via the DTC Fast Automated Securities Transfer (FAST)
Program. The Common Stock is not subject to any DTC "chill," freeze or similar restriction with respect to any DTC services,
including the clearing of shares of Common Stock through DTC.

 

(w)            Sarbanes-Oxley.
The Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002, as amended, which are applicable to it as
of the date hereof.

 

(x)            Certain
Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor or
consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction
Documents. The Investor shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other
Persons for fees of a type contemplated in this Section 4(w) that may be due in connection with the transactions contemplated
by the Transaction Documents.

 

(y)            Investment
Company. The Company is not required to be registered as, and immediately after receipt of any payment for the Purchase Shares will
not be required to be registered as, an "investment company" within the meaning of the Investment Company Act of 1940, as amended.

 

(z)            Listing
and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and the Company
has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common
Stock pursuant to the Exchange Act nor has the Company received any notification that the SEC is currently contemplating terminating
such registration. The Securities have been approved for listing on the Principal Market prior to issuance. The Company has taken no
action designed to, or likely to have the effect of, delisting the Common Stock from the Principal Market, nor has the Company received
any notice from any Person to the effect that the Company is not in compliance with the listing or maintenance requirements of the Principal
Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all
such listing and maintenance requirements.

 

(aa)     Accountants.
The Company’s accountants are set forth in the SEC Documents and, to the knowledge of the Company, such accountants are an independent
registered public accounting firm as required by the Securities Act.

 

(bb)     No
Market Manipulation. The Company has not, and to its knowledge no Person acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of,
any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company in connection with the transactions contemplated in this Agreement.

 

    -19-

    

    

 

(cc)     Shell
Company Status. The Company is not, and has never been, an issuer identified in Rule 144(i)(1) under the Securities Act
and has filed with the SEC current "Form 10 information" (as defined in Rule 144(i)(3) under the Securities
Act) at least 12 calendar months prior to the date of this Agreement reflecting its status as an entity that is not an issuer identified
in Rule 144(i)(1) under the Securities Act.

 

(dd)     No
Disqualification Events. None of the Company, any of its predecessors, any affiliated issuer, any director, executive officer,
other officer of the Company participating in the offering contemplated hereby, any beneficial owner of 20% or more of the
Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is
defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an
 "Issuer Covered Person") is subject to any of the "Bad Actor" disqualifications described in
Rule 506(d)(1)(i) to (viii) under the Securities Act (a "Disqualification Event"), except for a
Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company has exercised
reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event.

 

(ee)     Registration
Statement. The Company has prepared and filed the Shelf Registration Statement with the SEC in accordance with the Securities Act.
The Shelf Registration Statement was declared effective by order of the SEC on June 10, 2022. The Shelf Registration Statement is
effective pursuant to the Securities Act and available for the issuance of the Securities thereunder. No stop order suspending the effectiveness
of the Shelf Registration Statement has been issued by the SEC, and no proceeding for that purpose or pursuant to Section 8A of
the Securities Act against the Company or related to the offering of the Securities has been initiated or, to the knowledge of the Company,
threatened by the SEC. The "Plan of Distribution" section of the Prospectus permits the issuance of the Securities under the
terms of this Agreement. At the time the Shelf Registration Statement and any amendments thereto became effective, at the date of this
Agreement and at each deemed effective date thereof pursuant to Rule 430B(f)(2) of the Securities Act, the Shelf Registration
Statement and any amendments thereto complied and will comply in all material respects with the requirements of the Securities Act and
did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein not misleading; and the Base Prospectus and any Prospectus Supplement thereto, at the time
such Base Prospectus or such Prospectus Supplement thereto was issued and on the Commencement Date, complied and will comply in all material
respects with the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made,
not misleading; provided that this representation and warranty does not apply to statements in or omissions from any Prospectus Supplement
made in reliance upon and in conformity with information relating to the Investor furnished to the Company in writing by or on behalf
of the Investor expressly for use therein. The Company meets all of the requirements for the use of a registration statement on Form S-3
pursuant to the Securities Act for the offering and sale of the Securities contemplated by this Agreement in reliance on General Instruction
I.B.1., and the SEC has not notified the Company of any objection to the use of the form of the Registration Statement pursuant to Rule 401(g)(1) of
the Securities Act. The Company hereby confirms that the issuance of the Securities to the Investor in accordance with this Agreement
would not result in non-compliance with the Securities Act or any of the General Instructions to Form S-3. The Registration Statement,
as of its effective date, meets the requirements set forth in Rule 415(a)(1)(x) pursuant to the Securities Act. At the earliest
time after the filing of the Registration Statement that the Company or another offering participant made a bona fide offer (within the
meaning of Rule 164(h)(2) of the Securities Act) relating to any of the Securities, the Company was, and as of the date of
this Agreement the Company is, not an Ineligible Issuer (as defined in Rule 405 of the Securities Act). The Company has not distributed
any offering material in connection with the offering, issuance and sale of any of the Securities, other than the Shelf Registration
Statement or any amendment thereto, the Prospectus or any Prospectus Supplement required pursuant to Applicable Law or the Transaction
Documents. The Company has not made an offer relating to the Securities that would constitute a "free writing prospectus" as
defined in Rule 405 under the Securities Act.

 

    -20-

    

    

 

(ff)     Absence
of Schedules. In the event that on the date hereof, or the Commencement Date, the Company does not deliver any disclosure schedule
contemplated by this Agreement, the Company hereby acknowledges and agrees that each such undelivered disclosure schedule shall be deemed
to read as follows: "Nothing to Disclose."

 

		5.	COVENANTS.

 

(a)            Filing
of Current Report and Initial Prospectus Supplement. The Company agrees that it shall, within the time required under the Exchange
Act, file with the SEC a Current Report on Form 8-K relating to the transactions contemplated by, and describing the material terms
and conditions of, the Transaction Documents (the "Current Report"). The Company further agrees that it shall, within
the time required under Rule 424(b) under the Securities Act, file with the SEC the Initial Prospectus Supplement pursuant
to Rule 424(b) under the Securities Act specifically relating to the transactions contemplated by, and describing the material
terms and conditions of, the Transaction Documents, containing information previously omitted at the time of effectiveness of the Shelf
Registration Statement in reliance on Rule 430B under the Securities Act, and disclosing all information relating to the transactions
contemplated hereby required to be disclosed in the Shelf Registration Statement and the Prospectus as of the date of the Initial Prospectus
Supplement, including, without limitation, information required to be disclosed in the section captioned "Plan of Distribution"
in the Prospectus. The Investor acknowledges that it will be identified in the Initial Prospectus Supplement as an underwriter within
the meaning of Section 2(a)(11) of the Securities Act. The Company shall permit the Investor to review and comment upon the Current
Report and the Initial Prospectus Supplement at least two (2) Business Days prior to their filing with the SEC, the Company shall
give due consideration to all such comments. The Investor shall use its reasonable best efforts to provide any comments upon the Current
Report and the Initial Prospectus Supplement within one (1) Business Day from the date the Investor receives a substantially complete
draft thereof from the Company. The Investor shall furnish to the Company such information regarding itself, the Securities held by it
and the intended method of distribution thereof, including any arrangement between the Investor and any other Person relating to the
sale or distribution of the Securities, as shall be reasonably requested by the Company in connection with the preparation and filing
of the Current Report and the Initial Prospectus Supplement, and shall otherwise cooperate with the Company as reasonably requested by
the Company in connection with the preparation and filing of the Current Report and the Initial Prospectus Supplement with the SEC.

 

(b)            Blue
Sky. The Company shall take all such action, if any, as is reasonably necessary in order to obtain an exemption for or to register
or qualify (i) the issuance and the sale of the Securities to the Investor under this Agreement and (ii) any subsequent resale
of all Commitment Shares and all Purchase Shares by the Investor, in each case, under applicable securities or "Blue Sky" laws
of the states of the United States in such states as is reasonably requested by the Investor from time to time, and shall provide evidence
of any such action so taken to the Investor.

 

(c)            Listing/DTC.
The Company shall use commercially reasonable efforts to maintain, so long as any shares of Common Stock shall be so listed, such
listing of all Purchase Shares and Commitment Shares from time to time issuable hereunder. The Company shall use commercially
reasonable efforts to maintain the listing of the Common Stock on the Principal Market and shall use commercially reasonable efforts
to comply in all respects with the Company’s reporting, filing and other obligations under the Exchange Act, or rules and
regulations of the Principal Market. The Company shall not take any action that would reasonably be expected to result in the
delisting or suspension of the Common Stock on the Principal Market. The Company shall promptly, and in no event later than the
following Business Day, provide to the Investor copies of any notices it receives from any Person regarding the continued
eligibility of the Common Stock for listing on the Principal Market; provided, however, that the Company shall not be required to
provide the Investor copies of any such notice that the Company reasonably believes constitutes material non-public information that
the Company would not be required to contemporaneously publicly disclose in any report or statement filed with the SEC under the
Exchange Act or the Securities Act. The Company shall pay all fees and expenses in connection with
satisfying its obligations under this Section 5(c). The Company shall take all commercially reasonable action necessary
to ensure that its Common Stock can be transferred electronically as DWAC Shares.

 

    -21-

    

    

 

(d)            Prohibition
of Short Sales and Hedging Transactions. The Investor agrees that beginning on the date of this Agreement and ending on the date
of termination of this Agreement as provided in Section 11, the Investor and its agents (in their capacities as such), representatives
(in their capacities as such) and affiliates shall not in any manner whatsoever enter into or effect, directly or indirectly, any (i) "short
sale" (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Stock or (ii) hedging
transaction, which establishes a net short position with respect to the Common Stock.

 

(e)            Issuance
of Commitment Shares. In consideration for the Investor’s execution and delivery of this Agreement, the Company shall cause
the Transfer Agent to issue 347,222 shares of Common Stock (the "Commitment Shares") directly to the Investor in accordance
with Section 6 hereto and the Irrevocable Transfer Agent Instructions. For the avoidance of doubt, all of the Commitment
Shares shall be fully earned as of the date of this Agreement, whether or not the Commencement shall occur or any Purchase Shares are
purchased by the Investor under this Agreement and irrespective of any termination of this Agreement.

 

(f)            Due
Diligence; Non-Public Information. During the term of this Agreement, the Investor shall have the right, from time to time as
the Investor may reasonably deem appropriate, and upon reasonable advance notice to the Company, to perform reasonable due diligence
on the Company during normal business hours. The Company and its officers and employees shall provide material information and
reasonably cooperate with the Investor in connection with any reasonable request by the Investor related to the Investor’s due
diligence of the Company. Each party hereto agrees not to disclose any Confidential Information of the other party to any third
party and shall not use the Confidential Information for any purpose other than in connection with, or in furtherance of, the
transactions contemplated hereby. Each party hereto acknowledges that the Confidential Information shall remain the property of the
disclosing party and agrees that it shall take all reasonable measures to protect the secrecy of any Confidential Information
disclosed by the other party. The receiving party may disclose Confidential Information to the extent such information is required
to be disclosed by law, regulation or order of a court of competent jurisdiction or regulatory authority, provided that the
receiving party shall promptly notify the disclosing party when such requirement to disclose arises, and shall cooperate with the
disclosing party so as to enable the disclosing party to: (i) seek an appropriate protective order; and (ii) make any
applicable claim of confidentiality in respect of such Confidential Information; and provided, further, that the receiving party
shall disclose Confidential Information only to the extent required by the protective order or other similar order, if such an order
is obtained, and, if no such order is obtained, the receiving party shall disclose only the minimum amount of such Confidential
Information required to be disclosed in order to comply with the Applicable Law, regulation or order. In addition, any such
Confidential Information disclosed pursuant to this section shall continue to be deemed Confidential Information. Notwithstanding
anything in this Agreement to the contrary, (x) the Company shall not be obligated to provide the Investor with any information
that constitutes or may reasonably be considered to constitute material, non-public information pursuant to a request for
information hereunder, and the Company and the Investor agree that neither the Company nor any other Person acting on its behalf
shall provide the Investor or its agents or counsel with any information that constitutes or may reasonably be considered to
constitute material, non-public information, unless a simultaneous public announcement thereof is made by the Company in the manner
contemplated by Regulation FD, and (y) in the event that the Company believes that a notice or communication to the Investor or
any of its affiliates, attorneys, agents or representatives pursuant to this Agreement or any other Transaction Document contains
any material, nonpublic information, the Company shall so indicate to the Investor prior to delivery of such notice or
communication, and such indication shall provide the Investor the means to refuse to receive such notice or communication; and in
the absence of any such indication, the Investor and its affiliates, agents and representatives shall be allowed to presume that all
matters relating to such notice or communication do not constitute material, nonpublic information. In the event of any breach of
the foregoing covenants by the Company or any Person acting on its behalf (as determined in the reasonable good faith judgment of
the Investor), in addition to any other remedy provided herein or in the other Transaction Documents, if the Investor is holding any
Securities at the time of the disclosure of such material non-public information, the Investor shall have the right to make a public
disclosure, in the form of a press release, public advertisement or otherwise, of such material, non-public information without the
prior approval by the Company; provided the Investor shall have first provided notice to the Company that it believes it has
received information that constitutes material, non-public information; and the Company shall have at least two (2) Business
Days from such notice to either publicly disclose such material, non-public information or to demonstrate to the Investor that such
information does not constitute material, non-public information, and (assuming the Investor and Investor’s counsel disagree
in their reasonable good faith judgment with the Company’s determination) prior to any such disclosure by the Investor; and
the Company shall have failed to publicly disclose such material, non-public information. The Investor shall not have any liability
to the Company, any of its Subsidiaries, or any of their respective directors, officers, employees, stockholders or agents, for any
such disclosure in accordance with this Section 5(f). The Company understands and confirms that the Investor shall be
relying on the foregoing covenants in effecting transactions in securities of the Company. The Company hereby acknowledges and
agrees that, notwithstanding the provisions of this Section 5(f), if there is a breach or violation of any representation,
covenant, provision or agreement of the Company set forth in this Section 5(f) or Section 5(a) resulting in the
Investor obtaining or otherwise possessing material nonpublic information, neither the Investor nor any of the Investor’s
affiliates, attorneys, agents or representatives shall have any duty of trust or confidence (including any obligation under any
confidentiality or non-disclosure agreement entered into by the Investor with the Company) with respect to, or obligation not to
trade in any securities while aware of, such material nonpublic information.

 

    -22-

    

    

 

(g)            Purchase
Records. The Investor and the Company shall each maintain records showing the remaining Available Amount at any given time and the
dates and Purchase Amounts for each Regular Purchase, Accelerated Purchase and Additional Accelerated Purchase or shall use such other
method, reasonably satisfactory to the Investor and the Company.

 

(h)            Taxes.
The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and delivery
of any shares of Common Stock to the Investor made under this Agreement.

 

(i)            Use
of Proceeds. The Company will use the net proceeds from the offering for any corporate purpose at the sole discretion of the
Company.

 

(j)            Other
Transactions. The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement or transaction
in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the Company to perform
its obligations under the Transaction Documents, including, without limitation, the obligation of the Company to deliver the Commitment
Shares to the Investor in accordance with the terms of the Transaction Documents.

 

(k)            Aggregation. From
and after the date of this Agreement, neither the Company, nor or any of its affiliates will, and the Company shall use its reasonable
efforts to ensure that no Person acting on their behalf will, directly or indirectly, make any offers or sales of any security or solicit
any offers to buy any security, under circumstances that would cause this offering of the Securities by the Company to the Investor to
be aggregated with other offerings by the Company in a manner that would require stockholder approval pursuant to the rules of the
Principal Market on which any of the securities of the Company are listed or designated, unless stockholder approval is obtained before
the closing of such subsequent transaction in accordance with the rules of such Principal Market.

 

(l)            Limitation
on Variable Rate Transactions. From and after the date of this Agreement until the thirty-six (36) month anniversary of the date
of this Agreement (irrespective of any earlier termination of this Agreement), the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock involving a Variable Rate Transaction
other than with the Investor. "Variable Rate Transaction" includes, without limitation, an "equity line of credit"
or any similar transaction whereby an investor is irrevocably bound to purchase securities over a period of time from the Company at
a price based on the market price of the Company’s Common Stock at the time of each such purchase; provided, however,
that this Section 5(l) shall not be deemed to prohibit the issuance and sale of Common Stock pursuant to an "at-the-market
offering" by the Company exclusively through a registered broker-dealer acting as a sales agent of the Company pursuant to a written
agreement between the Company and such registered broker-dealer.

 

		6.	TRANSFER
                                            AGENT INSTRUCTIONS.

 

(a)  Commitment Shares.
On the date of this Agreement, the Company shall issue to the Transfer Agent (and any subsequent transfer agent) irrevocable instructions,
in the form agreed to prior to the date hereof (the "Irrevocable Transfer Agent Instructions"), to issue the Commitment
Shares in accordance with the terms of this Agreement. All Commitment Shares to be issued to or for the benefit of the Investor pursuant
to this Agreement shall be issued as DWAC Shares. The Company warrants to the Investor that, while the Agreement is effective, no instruction
other than the Irrevocable Transfer Agent Instructions referred to in this Section 6 will be given by the Company to the
Transfer Agent with respect to the Commitment Shares, and the Commitment Shares shall otherwise be freely transferable on the books and
records of the Company.

 

    -23-

    

    

 

(b)  Purchase Shares.
On the date of the Initial Prospectus Supplement, the Company shall issue to the Transfer Agent, and any subsequent transfer agent, irrevocable
instructions in the form agreed to prior to the date hereof (the "Commencement Irrevocable Transfer Agent Instructions")
to issue the Purchase Shares in accordance with the terms of this Agreement and the Registration Rights Agreement. All Purchase Shares
to be issued from and after Commencement to or for the benefit of the Investor pursuant to this Agreement shall be issued only as DWAC
Shares. The Company represents and warrants to the Investor that, while this Agreement is effective, no instruction other than as contemplated
by the Commencement Irrevocable Transfer Agent Instructions and any Notice of Effectiveness of Registration Statement (as defined in
the Registration Rights Agreement) will be given by the Company to the Transfer Agent with respect to the Purchase Shares from and after
Commencement, and no instruction or other communication to the Transfer Agent with respect to the issuance of the Purchase Shares shall
be made without the approval of the Investor. The Company shall provide confirmation of receipt by the Transfer Agent of all instructions
pursuant to the Commencement Irrevocable Transfer Agent Instructions with respect to Purchase Shares within one Business Day of delivery
of any Purchase Notice. The Purchase Shares covered by the Registration Statement shall otherwise be freely transferable on the books
and records of the Company.

 

		7.	CONDITIONS
                                            TO THE COMPANY’S RIGHT TO COMMENCE SALES OF SHARES OF COMMON STOCK.

 

The right of the Company
hereunder to commence sales of Purchase Shares is subject to the satisfaction, or where legally permissible, the waiver of each of the
following conditions:

 

(a)            The
Investor shall have executed each of the Transaction Documents and delivered the same to the Company;

 

(b)            The
representations and warranties of the Investor shall be true and correct in all material respects as of the date hereof and as of the
Commencement Date as though made at that time; and

 

(c)            No
stop order with respect to the Registration Statement shall be pending or threatened by the SEC.

 

		8.	CONDITIONS
                                            TO THE INVESTOR’S OBLIGATION TO PURCHASE SHARES OF COMMON STOCK.

 

The obligation of the Investor
to buy Purchase Shares under this Agreement is subject to the satisfaction or, where legally permissible, the waiver of each of the following
conditions on or prior to the Commencement Date and, once such conditions have been initially satisfied, there shall not be any ongoing
obligation to satisfy such conditions after the Commencement has occurred:

 

(a)            The
Company shall have executed each of the Transaction Documents and delivered the same to the Investor;

 

(b)            The
Company shall have issued or caused to be issued to the Investor a number of shares of Common Stock equal to the number of Commitment
Shares as DWAC Shares, in each case in accordance with Section 6;

 

(c)            The
Common Stock shall be listed on the Principal Market, and the Company shall have filed with The Nasdaq Stock Market a Notification Form:
Listing of Additional Shares for the listing of the Securities, and Nasdaq shall have raised no objection to the consummation of the
transactions contemplated by this Agreement;

 

(d)            The
Investor shall have received the opinion and negative assurances letter of the Company’s legal counsel dated as of the Commencement
Date substantially in the forms agreed prior to the date of this Agreement by the Company’s legal counsel and the Investor’s
legal counsel;

 

    -24-

    

    

 

(e)            The
representations and warranties of the Company shall be true and correct in all material respects (except to the extent that any of such
representations and warranties is already qualified as to materiality in Section 4 above, in which case, such representations
and warranties shall be true and correct without further qualification) as of the date hereof and as of the Commencement Date as though
made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct in all
material respects as of such date) and the Company shall have performed, satisfied and complied in all material respects with the covenants,
agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior
to the Commencement Date. The Investor shall have received a certificate, executed by the CEO, President or CFO of the Company, dated
as of the Commencement Date, to the foregoing effect in the form attached hereto as Exhibit B;

 

(f)            The
Board of Directors of the Company shall have adopted Signing Resolutions, which shall be in full force and effect without any amendment
or supplement thereto as of the Commencement Date;

 

(g)            As
of the Commencement Date, the Company shall have reserved out of its authorized and unissued Common Stock, solely for the purpose of
effecting purchases of Purchase Shares hereunder, 10,000,000 shares of Common Stock;

 

(h)            Each
of the Irrevocable Transfer Agent Instructions and the Commencement Irrevocable Transfer Agent Instructions shall have been delivered
to and acknowledged in writing by the Company and the Transfer Agent (or any successor transfer agent);

 

(i)            The
Company shall have delivered to the Investor a certificate of good standing of the Company in the State of Delaware issued by the Secretary
of State of the State of Delaware and a certificate or its equivalent evidencing the good standing of the Company as a foreign corporation
in any other jurisdiction where the Company is duly qualified to conduct business, in each case, as of a date within ten (10) Business
Days of the Commencement Date;

 

(j)            The
Company shall have delivered to the Investor a certified copy of the Charter as certified by the Secretary of State of the State of Delaware
within ten (10) Business Days of the Commencement Date;

 

(k)            The
Company shall have delivered to the Investor a secretary’s certificate executed by the Secretary of the Company, dated as of the
Commencement Date, in the form attached hereto as Exhibit C;

 

(l)            The
Shelf Registration Statement shall continue to be effective and no stop order with respect to the Shelf Registration Statement shall
be pending or threatened by the SEC. The Company shall have a maximum dollar amount of Common Stock registered under the Shelf
Registration Statement which is sufficient to issue to the Investor not less than (i) the full Available Amount worth of
Purchase Shares plus (ii) all of the Commitment Shares. The Current Report and the Initial Prospectus Supplement each shall
have been filed with the SEC, as required pursuant to Section 5(a), and copies of the Prospectus shall have been
delivered to the Investor in accordance with the terms of the Registration Rights Agreement. The Prospectus shall be current and
available for issuances and sales of all of the Securities by the Company to the Investor. Any other Prospectus Supplements required
to have been filed by the Company with the SEC under the Securities Act at or prior to the Commencement Date shall have been filed
with the SEC within the applicable time periods prescribed for such filings under the Securities Act. All reports, schedules,
registrations, forms, statements, information and other documents required to have been filed by the Company with the SEC at or
prior to the Commencement Date pursuant to the reporting requirements of the Exchange Act shall have been filed with the SEC within
the applicable time periods prescribed for such filings under the Exchange Act;

 

    -25-

    

    

 

(m)            No
Event of Default (as defined below) shall have occurred, and no event which, after notice and/or lapse of time, would reasonably be expected
to become an Event of Default shall have occurred;

 

(n)            The
Exchange Cap shall not have been reached (to the extent the Exchange Cap is applicable pursuant to Section 2(d) hereof);

 

(o)            All
federal, state and local governmental laws, rules and regulations applicable to the transactions contemplated by the Transaction
Documents and necessary for the execution, delivery and performance of the Transaction Documents and the consummation of the transactions
contemplated thereby in accordance with the terms thereof shall have been complied with, and all consents, authorizations and orders
of, and all filings and registrations with, all federal, state and local courts or governmental agencies and all federal, state and local
regulatory or self-regulatory agencies necessary for the execution, delivery and performance of the Transaction Documents and the consummation
of the transactions contemplated thereby in accordance with the terms thereof shall have been obtained or made, including, without limitation,
in each case those required under the Securities Act, the Exchange Act, applicable state securities or "Blue Sky" laws or applicable
rules and regulations of the Principal Market, or otherwise required by the SEC, the Principal Market or any state securities regulators;

 

(p)            No
statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed
by any federal, state or local or foreign court or governmental authority of competent jurisdiction which prohibits the consummation
of or which would materially modify or delay any of the transactions contemplated by the Transaction Documents;

 

(q)            No
action, suit or proceeding before any federal, state, local or foreign arbitrator or any court or governmental authority of competent
jurisdiction shall have been commenced or threatened, and no inquiry or investigation by any federal, state, local or foreign governmental
authority of competent jurisdiction shall have been commenced or threatened, against the Company, or any of the officers, directors or
affiliates of the Company, seeking to restrain, prevent or change the transactions contemplated by the Transaction Documents, or seeking
material damages in connection with such transactions; and

 

(r)            The
Company shall have provided the Investor with the information requested by the Investor in connection with its due diligence requests
in accordance with the terms of Section 5(f) hereof.

 

    -26-

    

    

 

		9.	INDEMNIFICATION.

 

In consideration of the Investor’s
execution and delivery of the Transaction Documents and acquiring the Purchase Shares hereunder and in addition to all of the Company’s
other obligations under the Transaction Documents, the Company shall defend, protect, indemnify and hold harmless the Investor and all
of its affiliates, equityholders, members, managers, officers, directors and employees and any of the foregoing Person’s agents
or other representatives (including, without limitation, those retained in connection with the transactions contemplated by this Agreement)
(collectively, the "Indemnitees") from and against any and all actions, causes of action, suits, claims, losses, costs,
penalties, fees, liabilities and damages, and reasonable expenses in connection therewith (irrespective of whether any such Indemnitee
is a party to the action for which indemnification hereunder is sought), and including reasonable and documented attorneys’ fees
and disbursements (the "Indemnified Liabilities"), incurred by any Indemnitee as a result of, or arising out of, or
relating to (a) any misrepresentation or breach of any representation or warranty made by the Company in the Transaction Documents
or any other certificate, instrument or document executed by the Company contemplated hereby or thereby, (b) any breach of any covenant,
agreement or obligation of the Company contained in the Transaction Documents or any other certificate, instrument or document executed
by the Company contemplated hereby or thereby, (c) any cause of action, suit or claim brought or made against such Indemnitee and
arising out of or resulting from the execution, delivery, performance or enforcement of the Transaction Documents or any other certificate,
instrument or document contemplated hereby or thereby, other than, in the case of clause (c) with respect to Indemnified Liabilities
which directly and primarily result from the fraud, gross negligence or willful misconduct of an Indemnitee. The indemnity in this Section 9
shall not apply to amounts paid in settlement of any claim if such settlement is effected without the prior written consent of the
Company, which consent shall not be unreasonably withheld, conditioned or delayed. To the extent that the foregoing undertaking by the
Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each
of the Indemnified Liabilities which is permissible under Applicable Law. Payment under this indemnification shall be made within thirty
(30) days from the date the Investor makes written request for it. A certificate containing reasonable detail as to the amount of such
indemnification submitted to the Company by the Investor shall be conclusive evidence, absent manifest error, of the amount due from
the Company to the Investor, provided that the Indemnitee shall undertake to repay any amounts paid to it hereunder if it is ultimately
determined, by a final and non-appealable order of a court of competent jurisdiction, that the Indemnitee is not entitled to be indemnified
against such Indemnified Liabilities by the Company pursuant to this Agreement. If any action shall be brought against any Indemnitee
in respect of which indemnity may be sought pursuant to this Agreement, such Indemnitee shall promptly notify the Company in writing,
and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Indemnitee.
Any Indemnitee shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees
and expenses of such counsel shall be at the expense of such Indemnitee, except to the extent that (i) the employment thereof has
been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume
such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of such separate counsel, a material
conflict on any material issue between the position of the Company and the position of such Indemnitee, in which case the Company shall
be responsible for the reasonable fees and expenses of no more than one such separate counsel (plus local counsel, if necessary). The
Company shall not, without the consent of the Indemnitee, consent to the entry of any judgment or enter into any settlement or other
compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnitee of a release
from all liability in respect to such claim or litigation or which includes any admission as to fault, culpability or failure to act
on the part of such Indemnitee.

 

		10.	EVENTS
                                            OF DEFAULT.

 

An "Event of Default"
shall be deemed to have occurred at any time as any of the following events occurs:

 

(a)            the
effectiveness of a Registration Statement registering the sale or resale of the Securities lapses for any reason (including, without
limitation, the issuance of a stop order or similar order) or such registration statement (or the prospectus forming a part thereof)
is unavailable to the Investor for sale or resale of any or all of the Securities to be issued to the Investor under the Transaction
Documents that are required to be included therein, and such lapse or unavailability continues for a period of ten (10) consecutive
Business Days or for more than an aggregate of thirty (30) Business Days in any 365-day period, but excluding a lapse or unavailability
where (i) the Company terminates a Registration Statement after the Investor has confirmed in writing that all of the Securities
covered thereby have been resold or (ii) the Company supersedes one Registration Statement with another Registration Statement,
including (without limitation) by terminating a prior Registration Statement when it is effectively replaced with a new Registration
Statement covering Securities (provided in the case of this clause (ii) that all of the Securities covered by the superseded (or
terminated) Registration Statement that have not theretofore been resold are included in the superseding (or new) Registration Statement);

 

    -27-

    

    

 

(b)            the
suspension of the Common Stock from trading on the Principal Market for a period of at least one (1) Business Day, provided that
the Company may not direct the Investor to purchase any shares of Common Stock during any such suspension;

 

(c)            the
delisting of the Common Stock from The NASDAQ Global Market provided, however, that the Common Stock is not immediately thereafter trading
on The NASDAQ Capital Market, The NASDAQ Global Select Market, the New York Stock Exchange, the NYSE American, the NYSE Arca, the OTC
Bulletin Board, or the OTCQB or the OTCQX operated by the OTC Markets Group, Inc. (or any nationally recognized successor to any
of the foregoing);

 

(d)            the
failure for any reason by the Transfer Agent to issue Purchase Shares to the Investor within two (2) Business Days after the applicable
Purchase Date, Accelerated Purchase Date or Additional Accelerated Purchase Date (as applicable) on which the Investor is entitled to
receive such Purchase Shares;

 

(e)            the
Company breaches any representation, warranty, covenant or other term or condition under this Agreement, any other Transaction Document
or any other certificate, instrument or document executed by the Company contemplated hereby or thereby, if such breach would reasonably
be expected to have a Material Adverse Effect and except, in the case of a breach of a covenant which is reasonably curable, only if
such breach continues for a period of at least five (5) Business Days;

 

(f)            if
any Person commences a proceeding against the Company pursuant to or within the meaning of any Bankruptcy Law;

 

(g)            if
the Company is at any time insolvent, or, pursuant to or within the meaning of any Bankruptcy Law, (i) commences a voluntary case,
(ii) consents to the entry of an order for relief against it in an involuntary case, (iii) consents to the appointment of a
Custodian of it or for all or substantially all of its property, or (iv) makes a general assignment for the benefit of its creditors
or is generally unable to pay its debts as the same become due;

 

(h)            a
court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (i) is for relief against the Company in
an involuntary case, (ii) appoints a Custodian of the Company or for all or substantially all of its property, or (iii) orders
the liquidation of the Company; or

 

(i)            if
at any time the Company is not eligible to transfer its Common Stock electronically as DWAC Shares or if the Company fails to maintain
the service of its Transfer Agent (or a successor Transfer Agent) with respect to the issuance of Purchase Shares under this Agreement,
including but not limited to, maintaining the effectiveness of the Commencement Irrevocable Transfer Instructions, payment of all fees
owed to the Transfer Agent and satisfaction of all conditions required by the Transfer Agent to issue Purchase Shares pursuant to the
Commencement Irrevocable Transfer Agent Instructions.

 

In addition to any other
rights and remedies under Applicable Law and this Agreement, so long as (i) an Event of Default has occurred and is continuing,
or if any event that, after notice and/or lapse of time, would reasonably be expected to become an Event of Default, has occurred and
is continuing or (ii) if at any time after the Commencement Date, the Exchange Cap is reached (to the extent the Exchange Cap is
applicable pursuant to Section 2(d) hereof), the Company shall not deliver to the Investor any Regular Purchase Notice, Accelerated
Purchase Notice or Additional Accelerated Purchase Notice.

 

    -28-

    

    

 

		11.	TERMINATION

 

This Agreement may be terminated
only as follows:

 

(a)            If
pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding
against the Company, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a
general assignment for the benefit of its creditors (any of which would be an Event of Default as described in Sections 10(f),
10(g) and 10(h) hereof), this Agreement shall automatically terminate without any liability or payment to the
Company (except as set forth below) without further action or notice by any Person.

 

(b)            At
any time after the Commencement Date, the Company shall have the option to terminate this Agreement for any reason or for no reason by
delivering notice (a "Company Termination Notice") to the Investor electing to terminate this Agreement without any
liability whatsoever of any party to any other party under this Agreement (except as set forth below). The Company Termination Notice
shall not be effective until one (1) Business Day after it has been received by the Investor.

 

(c)            This
Agreement shall automatically terminate on the date that the Company sells and the Investor purchases the full Available Amount as provided
herein, without any action or notice on the part of any party and without any liability whatsoever of any party to any other party under
this Agreement (except as set forth below).

 

(d)            If,
for any reason or for no reason, the full Available Amount has not been purchased in accordance with Section 2 of this Agreement
by the Maturity Date, this Agreement shall automatically terminate on the Maturity Date, without any action or notice on the part of
any party and without any liability whatsoever of any party to any other party under this Agreement (except as set forth below).

 

Except as set forth in Sections
11(a) (in respect of an Event of Default under Sections 10(f), 10(g) and 10(h)), and 11(d), any termination
of this Agreement pursuant to this Section 11 shall be effected by written notice from the Company to the Investor, or the
Investor to the Company, as the case may be, setting forth the basis for the termination hereof. The representations and warranties and
covenants of the Company and the Investor contained in Sections 3, 4, 5, and 6 hereof, the indemnification
provisions set forth in Section 9 hereof and the agreements and covenants set forth in Sections 10, 11 and
12 shall survive the execution and delivery of this Agreement and any termination of this Agreement. No termination of this Agreement
shall (i) affect the Company’s or the Investor’s rights or obligations under (A) this Agreement with respect to
any pending Regular Purchases, Accelerated Purchases, or Additional Accelerated Purchases, and the Company and the Investor shall complete
their respective obligations with respect to any pending Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases
under this Agreement and (B) the Registration Rights Agreement, which shall survive any such termination in accordance with its
terms, or (ii) be deemed to release the Company or the Investor from any liability for intentional misrepresentation or willful
breach of any of the Transaction Documents.

 

    -29-

    

    

 

 

		12.	MISCELLANEOUS.

 

(a)           Governing
Law; Jurisdiction; Jury Trial. The corporate laws of the State of Delaware shall govern all issues concerning the relative rights
of the Company and its stockholders. All other questions concerning the construction, validity, enforcement and interpretation of this
Agreement and the other Transaction Documents shall be governed by the internal laws of the State of New York, without giving effect
to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the
exclusive jurisdiction of and venue in the U.S. District Court for the Southern District of New York or, if that court does not have
subject matter jurisdiction, in any state court located in the City and County of New York, for the adjudication of any dispute hereunder
or under the other Transaction Documents or in connection herewith or therewith, or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue
of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY
WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

(b)           Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party. Signatures transmitted by Adobe
Sign, DocuSign, RightSignature, electronic mail, or other digital or electronic means will be treated as original signatures for all
purposes hereunder, each of which shall be of the same legal effect, validity, and enforceability as a manually executed signature.

 

(c)           Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

 

(d)           Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not
affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any
provision of this Agreement in any other jurisdiction.

 

(e)           Entire
Agreement. Except as to the Company’s obligation in respect of fees and expenses due and payable in connection with the negotiation
and entry into the Transaction Documents, which are set forth in that certain Term Sheet, dated June 29, 2022, the Transaction Documents
supersede all other prior oral or written agreements between the Investor, the Company, their affiliates and Persons acting on their
behalf with respect to the subject matter thereof, and this Agreement, the other Transaction Documents and the instruments referenced
herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically
set forth herein or therein, neither the Company nor the Investor makes any representation, warranty, covenant or undertaking with respect
to such matters. The Company acknowledges and agrees that it has not relied on, in any manner whatsoever, any representations or statements,
written or oral, other than as expressly set forth in the Transaction Documents. The Investor acknowledges and agrees that it has not
relied on, in any manner whatsoever, any representations or statements, written or oral, other than as expressly set forth in the Transaction
Documents.

 

    -30-

    

    

 

(f)            Notices.
Any notices, consents or other communications required or permitted to be given under the terms of this Agreement must be in writing
and will be deemed to have been delivered: (i) upon receipt when delivered personally; (ii) upon receipt when sent by facsimile
or email (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or
(iii) one Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to
the party to receive the same. The addresses for such communications shall be:

 

If to the Company:

 

	Zynerba Pharmaceuticals, Inc.
	80 W. Lancaster Avenue, Suite 300
	Devon, Pennsylvania 19333
	E-mail:	parkera@zynerba.com
	Attention:	Albert P. Parker, Chief Legal Officer
	 	 
	With a copy to (which shall
    not constitute notice or service of process):
	 	 
	Troutman Pepper Hamilton Sanders
    LLP
	3000 Two Logan Square
	Eighteenth and Arch Streets
	Philadelphia, PA 19103
	Telephone:	(215) 981-4000
	Facsimile:	(215) 981-4750
	Email:	rachael.bushey@troutman.com; jennifer.porter@troutman.com
	Attention:	Rachael Bushey and Jennifer Porter
	 	 
	If to the Investor:
	 	 
	Lincoln Park Capital Fund,
    LLC
	440 North Wells St., Suite 410
	Chicago, IL 60654
	Telephone:	[***]
	Facsimile:	[***]
	E-mail:	[***]
	Attention:	[***]
	 	 
	With a copy to (which shall
    not constitute notice or service of process):
	 	 
	Katten Muchin Rosenman LLP
	525 W. Monroe St.
	Chicago, IL 60661
	Telephone:	(312) 902-5493
	E-mail:	mark.wood@katten.com
	Attention:	Mark D. Wood,Esq.
	 	 
	If to the Transfer Agent:
	 	 
	American Stock Transfer &
    Trust Company, LLC
	6201 15th Avenue
	Brooklyn, NY 11219
	Telephone:	(718) 921-8300
	Facsimile:	(718) 765-8713
	Email:	pvelez@astfinancial.com
	Attention:	Philip Velez

 

or at such other address, email address and/or
facsimile number and/or to the attention of such other Person as the recipient party has specified by written notice given to each other
party three (3) Business Days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient
of such notice, consent or other communication, (B) mechanically or electronically generated by the sender’s facsimile machine
or email account containing the time, date, and recipient facsimile number or email address, as applicable, or (C) provided by a
nationally recognized overnight delivery service, shall be rebuttable evidence of personal service, receipt by facsimile or email or
deposit with a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.

 

    -31-

    

    

 

(g)            Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns.
The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor,
including by merger or consolidation. The Investor may not assign its rights or obligations under this Agreement.

 

(h)            No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

(i)            Publicity.
The Company shall afford the Investor and its counsel with the opportunity to review and comment upon, shall consult with the Investor
and its counsel on the form and substance of, and shall give due consideration to all such comments from the Investor or its counsel
on, the Prospectus Supplement, any press release or any Current Report on Form 8-K by or on behalf of the Company relating to the
Investor, its purchases hereunder or any aspect to the Transaction Documents or the transactions contemplated thereby, not less than
24 hours prior to the issuance, filing or public disclosure thereof; provided, however, that the Company shall not be required
to provide the Investor any disclosures that are materially similar to those previously reviewed by the Investor.

 

(j)            Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to
consummate and make effective, as soon as reasonably possible, the Commencement, and to carry out the intent and accomplish the purposes
of this Agreement and the consummation of the transactions contemplated hereby.

 

(k)            No
Financial Advisor, Placement Agent, Broker or Finder. The Company represents and warrants to the Investor that it has not engaged
any financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. The Investor represents
and warrants to the Company that it has not engaged any financial advisor, placement agent, broker or finder in connection with the transactions
contemplated hereby. The Company shall be responsible for the payment of any fees or commissions, if any, of any financial advisor, placement
agent, broker or finder relating to or arising out of the transactions contemplated hereby. The Company shall pay, and hold the Investor
harmless against, any liability, loss or expense (including, without limitation, reasonable attorneys’ fees and out of pocket expenses)
arising in connection with any such claim made by a third party for any such fees or commissions.

 

(l)            No
Strict Construction; Rule of Construction. The language used in this Agreement will be deemed to be the language chosen by the
parties to express their mutual intent, and no rules of strict construction will be applied against any party. For the purposes
of this Agreement, except to the extent that the context otherwise requires: (i) when a reference is made in this Agreement to an
Article, Section, Exhibit or Schedule, such reference is to an Article or Section of, or an Exhibit or Schedule to,
this Agreement unless otherwise indicated; (ii) headings for this Agreement are for reference purposes only and do not affect in
any way the meaning or interpretation of this Agreement; (iii) whenever the words "include," "includes" or "including"
(or similar terms) are used in this Agreement, they are deemed to be followed by the words "without limitation"; (iv) the
words "hereof," "herein" and "hereunder" and words of similar import, when used in this Agreement, refer
to this Agreement as a whole and not to any particular provision of this Agreement; (v) the definitions contained in this Agreement
are applicable to the singular as well as the plural forms of such terms;; (vi) references to a Person are also to its permitted
successors and assigns; and (vii) the use of "or" is not intended to be exclusive unless expressly indicated otherwise.

 

    -32-

    

    

 

(m)          Remedies,
Other Obligations, Breaches and Injunctive Relief. The Investor’s remedies provided in this Agreement, including, without limitation,
the Investor’s remedies provided in Section 9, shall be cumulative and in addition to all other remedies available
to the Investor under this Agreement, at law or in equity (including a decree of specific performance and/or other injunctive relief).
No remedy of the Investor contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy and
nothing herein shall limit the Investor’s right to pursue actual damages for any failure by the Company to comply with the terms
of this Agreement. The Company acknowledges that a material breach by it of its obligations hereunder will cause irreparable harm to
the Investor and that the remedy at law for any such material breach may be inadequate. The Company therefore agrees that, in the event
of any such material breach or threatened material breach, the Investor party shall be entitled, in addition to all other available remedies,
to an injunction restraining any material breach, without the necessity of showing economic loss and without any bond or other security
being required.

 

(n)           Amendment
and Waiver; Failure or Indulgence Not Waiver. No provision of this Agreement (i) may be amended other than by a written instrument
signed by both parties hereto and (ii) may be waived other than in a written instrument signed by the party against whom enforcement
of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other
right, power or privilege.

 

* * * * *

 

    -33-

    

    

 

IN
WITNESS WHEREOF, the Investor and the Company have caused this Purchase Agreement to be duly executed as of the date first
written above.

 

	 	THE COMPANY:
	 	 
	 	ZYNERBA PHARMACEUTICALS, INC.
	 	 
	 	By:	/s/
    Armando Anido                     

	 	Name: Armando Anido
	 	Title: Chief Executive Officer

 

	 	THE INVESTOR:
	 	 
	 	LINCOLN PARK CAPITAL FUND, LLC
	 	BY: LINCOLN PARK CAPITAL, LLC
	 	BY: ROCKLEDGE CAPITAL CORPORATION
	 	 
	 	By:	/s/
    Josh Scheinfeld          

	 	Name: Josh Scheinfeld
	 	Title: President

 

    -34-

    

    

 

EXHIBITS

 

	Exhibit A	Signing Resolutions
	Exhibit B	Form of Officer’s Certificate
	Exhibit C	Form of Secretary’s Certificate

 

     

     

    

 

EXHIBIT A

 

FORM OF COMPANY RESOLUTIONS

FOR SIGNING PURCHASE AGREEMENT

 

In accordance with the General
Corporation Law of the State of Delaware (the "DGCL"), the undersigned, constituting all of the members of the
Board of Directors (the "Board") of Zynerba Pharmaceuticals, Inc.,
a Delaware corporation (the "Company"), hereby adopt the following resolutions by unanimous written consent
pursuant to Section 141(f) of the DGCL and direct that this consent be filed with the minutes of the proceedings of the Board:

 

Whereas,
there has been presented to the Board a draft of the Purchase Agreement (the "Purchase Agreement") by and between
the Company and Lincoln Park Capital Fund, LLC ("Lincoln Park"), providing for the purchase by Lincoln Park of
up to Twenty Million Dollars ($20,000,000) of the Company’s common stock, $0.001 par value per share (the "Common Stock")
and a draft of the Registration Rights Agreement (the "Registration Rights Agreement") by and between the Company
and Lincoln Park providing for the registration of the shares of the Company’s Common Stock issuable in respect of the Purchase
Agreement on behalf of the Company; and

 

Whereas,
after careful consideration of the Purchase Agreement, the documents incident thereto and other factors deemed relevant by the Board,
the Board has determined that it is advisable and in the best interests of the Company and its stockholders to engage in the transactions
contemplated by the Purchase Agreement, including, but not limited to, the payment of $400,000 to Lincoln Park as a commitment fee in
the form of 347,222 shares of Common Stock (the "Commitment Shares"), and the sale of shares of Common Stock
to Lincoln Park up to the available amount under the Purchase Agreement (the "Purchase Shares") and to register
such shares as contemplated by the Registration Rights Agreement.

 

Transaction Documents

 

Now,
Therefore, Be It Resolved, that the transactions described in the Purchase Agreement are hereby approved and each of Armando
Anido, James E. Fickenscher, and Albert P. Parker (the "Authorized Officers") are severally authorized to execute
and deliver the Purchase Agreement, and any other agreements or documents contemplated thereby including, without limitation, the Registration
Rights Agreement, with such amendments, changes, additions and deletions as the Authorized Officers may deem to be appropriate and approve
on behalf of, the Company, such approval to be conclusively evidenced by the signature of an Authorized Officer thereon; and

 

Further
Resolved, that the terms and provisions of the Registration Rights Agreement by and among the Company and Lincoln Park are
hereby approved and the Authorized Officers are authorized to execute and deliver the Registration Rights Agreement (pursuant to the
terms of the Purchase Agreement), with such amendments, changes, additions and deletions as the Authorized Officer may deem appropriate
and approve on behalf of, the Company, such approval to be conclusively evidenced by the signature of an Authorized Officer thereon;
and

 

Further
Resolved, that the terms and provisions of the forms of Irrevocable Transfer Agent Instructions, Commencement Irrevocable
Transfer Agent Instructions and Notice of Effectiveness of Registration Statement (collectively, the "Instructions")
provided to the Board for review are hereby approved and the Authorized Officers are authorized to execute and deliver the Instructions
on behalf of the Company in accordance with the Purchase Agreement, with such amendments, changes, additions and deletions as the Authorized
Officers may deem appropriate and approve on behalf of, the Company, such approval to be conclusively evidenced by the signature of an
Authorized Officer thereon.

 

     

     

    

 

Execution of Purchase Agreement

 

Further
Resolved, that the Company be and it hereby is authorized to execute the Purchase Agreement providing for the purchase of
up to Twenty Million Dollars ($20,000,000) of the Company’s Common Stock; and

 

Issuance of Common Stock

 

Further
Resolved, that the Company is hereby authorized to issue to Lincoln Park 347,222 shares of Common Stock as the Commitment
Shares, and that upon issuance of the Commitment Shares pursuant to the Purchase Agreement the Commitment Shares shall be duly authorized,
validly issued, fully paid and nonassessable with no personal liability attaching to the ownership thereof; and

 

Further
Resolved, that the Company is hereby authorized to issue shares of Common Stock upon the purchase of Purchase Shares up to
the Available Amount under the Purchase Agreement in accordance with the terms of the Purchase Agreement and that, upon issuance of the
Purchase Shares pursuant to the Purchase Agreement, the Purchase Shares will be duly authorized, validly issued, fully paid and nonassessable
with no personal liability attaching to the ownership thereof; and

 

Further
Resolved, that the Company shall initially reserve 10,000,000 shares of Common Stock for issuance as Purchase Shares
under the Purchase Agreement.

 

Filings with the SEC

 

Further
Resolved, that the Company adopt one or more prospectus supplements and preliminary prospectus supplements, if applicable,
in the form approved by the Authorized Officers, as a prospectus supplement and preliminary prospectus supplement to be used in connection
with the Purchase Shares and Commitment Shares as a takedown off of the Company’s existing Shelf Registration Statement to register
the issuance of the Purchase Shares and Commitment Shares to Lincoln Park and the resale thereof, and any prospectus supplement and preliminary
prospectus supplement, in the form approved by the Authorized Officers, is hereby ratified, confirmed and approved in all respects, the
filing thereof to be conclusive evidence of the due authorization and approval thereof by the Company; and that the Authorized Officers
be, and each of them hereby is, instructed to file the prospectus supplements and preliminary prospectus supplements, if applicable,
with the SEC under Rule 424(b) promulgated under the Securities Act of 1933, as amended; and

 

Further
Resolved, that the Authorized Officers be, and each of them hereby is, authorized and empowered, for and on behalf of the
Company, to file any notifications required to be filed by the Company with Nasdaq and the Financial Industry Regulatory Authority, Inc.
as a result of the Purchase Agreement or the issuance of the Purchase Shares and Commitment Shares and to apply to list all the Offering
Shares on Nasdaq; and that the Authorized Officers be, and each of them hereby is, authorized and empowered, for and on behalf of the
Company, to cause the execution and delivery of any and all documents, to cause the payment of all listing and related fees and to take
any and all further actions they deem necessary, appropriate or desirable to carry out the intent of the foregoing, any such determination
to be conclusively evidenced by the execution and delivery of such documents or instruments or the doing or performing of such acts or
things.

 

     

     

    

 

Approval of Actions

 

Further
Resolved, that, without limiting the foregoing, the Authorized Officers are, and each of them hereby is, authorized and directed
to proceed on behalf of the Company and to take all such steps as deemed necessary or appropriate, with the advice and assistance of
counsel, to cause the Company to consummate the agreements referred to herein and to perform its obligations under such agreements; and

 

Further
Resolved, that the Authorized Officers be, and each of them hereby is, authorized, empowered and directed on behalf of and
in the name of the Company, to take or cause to be taken all such further actions and to execute and deliver or cause to be executed
and delivered all such further agreements, amendments, documents, certificates, reports, schedules, applications, notices, letters and
undertakings and to incur and pay all such fees and expenses as in their judgment shall be necessary, proper or desirable to carry into
effect the purpose and intent of any and all of the foregoing resolutions, and that all actions heretofore taken by any officer or director
of the Company in connection with the transactions contemplated by the agreements described herein are hereby approved, ratified and
confirmed in all respects.

 

Further
Resolved, that this Action by Unanimous Written Consent shall be filed with
the minutes of the proceedings of the Board. This Action may be signed in one or more counterparts, each of which shall be deemed an
original, and all of which shall constitute one instrument.

 

[SIGNATURE PAGE FOLLOWS]

 

     

     

    

 

IN
WITNESS WHEREOF, the undersigned have executed this Unanimous Written Consent of the Board of Directors of Zynerba Pharmaceuticals, Inc.
as of date written below.

 

	By:	 	 	By:	 
	Date:	 	 	Date:
	 	 	 	 
	By:	 	 	By:	 
	Date:	 	 	Date:
	 	 	 	 
	By:	 	 	By:	 
	Date:	 	 	Date:
	 	 	 	 
	By:	 	 	 
	Date:]	 	 	 

 

     

     

    

 

EXHIBIT B

 

FORM OF OFFICER’S CERTIFICATE

 

This Officer’s Certificate
("Certificate") is being delivered pursuant to Section 8(e) of that certain Purchase Agreement dated
as of July 21, 2022, ("Purchase Agreement"), by and between ZYNERBA PHARMACEUTICALS, INC., a Delaware
corporation (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC (the "Investor"). Terms used
herein and not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement.

 

The undersigned, Armando
Anido, Chief Executive Officer of the Company, hereby certifies, on behalf of the Company and not in his individual capacity, as follows:

 

1.            I
am the Chief Executive Officer of the Company;

 

2.            The
representations and warranties of the Company contained in the Purchase Agreement are true and correct in all material respects (except
to the extent that any of such representations and warranties is already qualified as to materiality in Section 4 of the Purchase
Agreement, in which case, such representations and warranties are true and correct without further qualification) as of the date of the
Purchase Agreement and as of the Commencement Date as though made at that time (except for representations and warranties that speak
as of a specific date, in which case such representations and warranties are true and correct in all material respects as of such date);

 

3.            The
Company has performed, satisfied and complied, in all material respects, with the covenants, agreements and conditions required by the
Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement Date, to the extent
not otherwise waived.

 

4.            The
Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy Law nor
does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary
bankruptcy or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as they become due.

 

     

     

    

 

IN
WITNESS WHEREOF, I have hereunder signed my name on this ___ day of ___________, 2022.

 

	 	 
	 	Name: Armando Anido
	 	Title: Chief Executive Officer

 

The undersigned as Secretary
of ZYNERBA PHARMACEUTICALS, INC., a Delaware corporation, hereby certifies that Armando Anido is the duly elected, appointed,
qualified and acting Chief Executive Officer of the Company, and that the signature appearing above is his genuine signature.

 

	 	 
	 	Albert P. Parker, Secretary

 

     

     

    

 

EXHIBIT C

 

FORM OF SECRETARY’S CERTIFICATE

 

This Secretary’s Certificate
("Certificate") is being delivered pursuant to Section 8(k) of that certain Purchase Agreement dated
as of July 21, 2022 ("Purchase Agreement"), by and between ZYNERBA PHARMACEUTICALS, INC., a Delaware
corporation (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC (the "Investor"), pursuant to
which the Company may sell to the Investor up to Twenty Million Dollars ($20,000,000) of the Company’s Common Stock, $0.001 par
value per share (the "Common Stock"). Terms used herein and not otherwise defined shall have the meanings ascribed to
them in the Purchase Agreement.

 

The undersigned, Albert P.
Parker, Corporate Secretary of the Company, hereby certifies, on behalf of the Company and not in his individual capacity, as follows:

 

1.            I
am the Corporate Secretary of the Company.

 

2.            Attached
hereto as Exhibit A and Exhibit B are true, correct and complete copies of the Company’s Amended and Restated
Bylaws ("Bylaws") and Sixth Amended and Restated Certificate of Incorporation ("Charter"), and no action
has been taken by the Company, its directors, officers or stockholders, in contemplation of the filing of any further amendment relating
to or affecting the Bylaws or Charter.

 

3.            Attached
hereto as Exhibit C are true, correct and complete copies of the resolutions duly adopted by the Board of Directors of the
Company by unanimous written consent effective as of July 19, 2022. Such resolutions have not been amended, modified or rescinded
and remain in full force and effect and such resolutions are the only resolutions adopted by the Board of Directors, or any committee
thereof, or the stockholders of the Company relating to or affecting (i) the entering into and performance of the Purchase Agreement,
or the issuance, offering and sale of the Purchase Shares and the Commitment Shares and (ii) and the performance of the Company
of its obligation under the Transaction Documents as contemplated therein.

 

4.            As
of the date hereof, the authorized, issued and reserved capital stock of the Company is as set forth on Exhibit D hereto.

 

     

     

    

 

IN
WITNESS WHEREOF, I have hereunder signed my name on this 21st day of July, 2022.

 

	 	 	 
	 	Corporate Secretary	 

 

The undersigned as Chief Executive Officer of
ZYNERBA PHARMACEUTICALS, INC., a Delaware corporation, hereby certifies that Albert P. Parker is the duly elected, appointed,
qualified and acting Secretary of Zynerba Pharmaceuticals, Inc., and that the signature appearing above is his genuine signature.

 

	 	 	 
	 	Armando Anido, Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]